<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus - Ronellenfitsch, U - 2013 | Cochrane Library</title> <meta content="Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus - Ronellenfitsch, U - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008107.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus - Ronellenfitsch, U - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008107.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008107.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus" name="citation_title"/> <meta content="Ulrich Ronellenfitsch" name="citation_author"/> <meta content="University Medical Centre Mannheim, University of Heidelberg" name="citation_author_institution"/> <meta content="ulrich.ronellenfitsch@umm.de" name="citation_author_email"/> <meta content="Matthias Schwarzbach" name="citation_author"/> <meta content="Klinikum Frankfurt Hoechst" name="citation_author_institution"/> <meta content="Ralf Hofheinz" name="citation_author"/> <meta content="University Medical Centre Mannheim, University of Heidelberg" name="citation_author_institution"/> <meta content="Peter Kienle" name="citation_author"/> <meta content="University Medical Centre Mannheim, University of Heidelberg" name="citation_author_institution"/> <meta content="Meinhard Kieser" name="citation_author"/> <meta content="University Hospital Heidelberg" name="citation_author_institution"/> <meta content="Tracy E Slanger" name="citation_author"/> <meta content="Institute for Quality and Efficiency in Health Care (IQWiG)" name="citation_author_institution"/> <meta content="Katrin Jensen" name="citation_author"/> <meta content="University Hospital Heidelberg" name="citation_author_institution"/> <meta content="GE Adenocarcinoma Meta‐analysis Group" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD008107.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/05/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008107.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008107.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008107.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Esophagogastric Junction [surgery]; Adenocarcinoma [mortality, *therapy]; Antineoplastic Agents [therapeutic use]; Carcinoma, Squamous Cell [mortality, therapy]; Chemoradiotherapy [methods]; Combined Modality Therapy [methods]; Esophageal Neoplasms [mortality, *therapy]; Randomized Controlled Trials as Topic; Stomach Neoplasms [mortality, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008107.pub2&amp;doi=10.1002/14651858.CD008107.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="u3GUW7vS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008107\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008107\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008107.pub2",title:"Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus",firstPublishedDate:"May 31, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=u3GUW7vS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008107.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008107.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008107.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008107.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008107.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008107.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008107.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008107.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008107.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008107.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2069 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008107.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-sec-0093"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/appendices#CD008107-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/table_n/CD008107StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/table_n/CD008107StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#CD008107-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ulrich Ronellenfitsch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#CD008107-cr-0003">Matthias Schwarzbach</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#CD008107-cr-0004">Ralf Hofheinz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#CD008107-cr-0005">Peter Kienle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#CD008107-cr-0006">Meinhard Kieser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#CD008107-cr-0007">Tracy E Slanger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#CD008107-cr-0008">Katrin Jensen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information#CD008107-cr-0009">GE Adenocarcinoma Meta‐analysis Group</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information/en#CD008107-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 May 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008107.pub2">https://doi.org/10.1002/14651858.CD008107.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008107-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008107-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008107-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008107-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008107-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008107-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008107-abs-0001" lang="en"> <section id="CD008107-sec-0001"> <h3 class="title" id="CD008107-sec-0001">Background</h3> <p>The outcome of patients with locally advanced gastroesophageal adenocarcinoma (adenocarcinoma of the esophagus, gastroesophageal (GE) junction, and stomach) is poor. There is conflicting evidence regarding the effects of perioperative chemotherapy on survival and other outcomes. </p> </section> <section id="CD008107-sec-0002"> <h3 class="title" id="CD008107-sec-0002">Objectives</h3> <p>To assess the effect of perioperative chemotherapy for gastroesophageal adenocarcinoma on survival and other clinically relevant outcomes in the overall population of participants in randomized controlled trials (RCTs) and in prespecified subgroups. </p> </section> <section id="CD008107-sec-0003"> <h3 class="title" id="CD008107-sec-0003">Search methods</h3> <p>We performed computerized searches in the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Review of Effectiveness (DARE), the Cochrane Database of Systematic Reviews (CDSR) from <i>The Cochrane Library</i>, MEDLINE (1966 to May 2011), EMBASE (1980 to May 2011), and LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud), combining the Cochrane highly sensitive search strategy with specific search terms. Moreover, we handsearched several online databases, conference proceedings, and reference lists of retrieved papers. </p> </section> <section id="CD008107-sec-0004"> <h3 class="title" id="CD008107-sec-0004">Selection criteria</h3> <p>We included RCTs which randomized patients with gastroesophageal adenocarcinoma, in the absence of distant metastases, to receive either chemotherapy with or without radiotherapy followed by surgery, or surgery alone. </p> </section> <section id="CD008107-sec-0005"> <h3 class="title" id="CD008107-sec-0005">Data collection and analysis</h3> <p>Two independent review authors identified eligible trials. We solicited individual patient data (IPD) from all selected trials. We performed meta‐analyses based on intention‐to‐treat populations using the two‐stage method to combine IPD with aggregate data from RCTs for which IPD were unavailable. We combined data from all trials providing IPD in a Cox proportional hazards model to assess the effect of several covariables on overall survival. </p> </section> <section id="CD008107-sec-0006"> <h3 class="title" id="CD008107-sec-0006">Main results</h3> <p>We identified 14 RCTs with 2422 eligible patients. For eight RCTs with 1049 patients (43.3%), we were able to obtain IPD. Perioperative chemotherapy was associated with significantly longer overall survival (hazard ratio (HR) 0.81; 95% confidence interval (CI) 0.73 to 0.89). This corresponds to a relative survival increase of 19% or an absolute survival increase of 9% at five years. This survival advantage was consistent across most subgroups. There was a trend towards a more pronounced treatment effect for tumors of the GE junction compared to other sites, and for combined chemoradiotherapy as compared to chemotherapy in tumors of the esophagus and GE junction. Resection with negative margins was a strong predictor of survival. Multivariable analysis showed that tumor site, performance status, and age have an independent significant effect on survival. Moreover, there was a significant interaction of the effect of perioperative chemotherapy with age (larger treatment effect in younger patients). Perioperative chemotherapy also showed a significant effect on several secondary outcomes. It was associated with longer disease‐free survival, higher rates of R0 resection, and more favorable tumor stage upon resection, while there was no association with perioperative morbidity and mortality. </p> </section> <section id="CD008107-sec-0007"> <h3 class="title" id="CD008107-sec-0007">Authors' conclusions</h3> <p>Perioperative chemotherapy for resectable gastroesophageal adenocarcinoma increases survival compared to surgery alone. It should thus be offered to all eligible patients. There is a trend to a larger survival advantage for tumors of the GE junction as compared to other sites and for chemoradiotherapy as compared to chemotherapy in esophageal and GE junction tumors. Likewise, there is an interaction between age and treatment effect, with younger patients having a larger survival advantage, and no survival advantage for elderly patients. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008107-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008107-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008107-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008107-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008107-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008107-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008107-abs-0005" lang="en"> <h3>Chemotherapy before surgery in patients with adenocarcinoma of the esophagus, the gastroesophageal junction, and the stomach </h3> <p>This systematic review uses the data of individual patients from eight and published data from another six randomized controlled trials. We found that the administration of chemotherapy before surgery leads to longer survival in patients with adenocarcinoma of the esophagus, the junction between esophagus and stomach, and the stomach. The findings suggest that patients whose tumor is in the junction between esophagus and stomach and younger patients benefit most from the chemotherapy. Moreover, the addition of radiation to the chemotherapy seems to yield an additional advantage to patients, at least in tumors of the esophagus and the junction between esophagus and stomach. Chemotherapy before surgery does not increase the risk of suffering a complication during or after surgery. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008107-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008107-sec-0094"></div> <h3 class="title" id="CD008107-sec-0095">Implications for practice</h3> <section id="CD008107-sec-0095"> <p>Perioperative chemotherapy and chemoradiotherapy appear to lead to prolonged survival in patients with gastroesophageal adenocarcinoma. It should thus be considered standard of care and offered to all eligible patients. There is a trend to a larger survival advantage for tumors of the gastroesophageal junction as compared to other sites and for chemoradiotherapy as compared to chemotherapy. Likewise, there is an interaction between age and treatment effect, with younger patients experiencing a larger survival advantage and no survival advantage for elderly patients. Fears of elevated postoperative morbidity and mortality following perioperative chemotherapy do not seem to be justified. </p> </section> <h3 class="title" id="CD008107-sec-0096">Implications for research</h3> <section id="CD008107-sec-0096"> <p>The results of our subgroup analyses, such as the more pronounced survival advantage found for tumors of the gastroesophageal junction as compared to other sites, in younger patients compared to older ones, and for chemoradiotherapy compared to chemotherapy, need to be validated in prospective trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008107-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008107-sec-0029"></div> <div class="table" id="CD008107-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus <br/> <b>Settings:</b> <br/> <b>Intervention:</b> perioperative chemotherapy <br/> <b>Comparison:</b> primary surgery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Primary surgery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Perioperative chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival among all patients</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.81</b> <br/> (0.73 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2422 <br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disease‐free survival (landmark time 6 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.84</b> <br/> (0.69 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>931 <br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by type of data ‐ Individual patient data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.80</b> <br/> (0.66 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1049 <br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by type of data ‐ Aggregated data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.81</b> <br/> (0.72 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1373 <br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by tumor site ‐ Esophagus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.87</b> <br/> (0.73 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>473 <br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by tumor site ‐ GE junction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b> <br/> (0.54 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>470 <br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by tumor site ‐ Stomach</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.94</b> <br/> (0.82 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>828 <br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>GE:</b> gastroesophageal; <b>HR:</b> hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Four out of the six studies included in this analysis have a high overall risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008107-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus <br/> <b>Settings:</b> <br/> <b>Intervention:</b> perioperative chemotherapy <br/> <b>Comparison:</b> primary surgery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Primary surgery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Perioperative chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.83</b> <br/> (0.75 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2033 <br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.70</b> <br/> (0.50 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>389 <br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of tumor‐free resection margin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 100</b> <br/> (67 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.42</b> <br/> (0.97 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1665 <br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tumor stage at resection (T0 to T2 vs T3 to T4)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b> <br/> (34 to 54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.53</b> <br/> (1.02 to 2.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1410 <br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tumor stage at resection (N0 vs N+)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 100</b> <br/> (25 to 47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.43</b> <br/> (1.48 to 3.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1507 <br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postoperative morbidity</b> <br/> RD </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 100</b> <br/> (28 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1397 <br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risks were calculated from pooled risk differences: RD 0.01 (‐0.03 to 0.05)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postoperative mortality</b> <br/> RD </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> <br/> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1606 <br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risks were calculated from pooled risk differences:RD 0.00 (‐0.01 to 0.02)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>HR:</b> hazard ratio; <b>RD:</b> risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Heterogeneous trial results. <br/> <sup>2</sup>Funnel plot suggests publication bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008107-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008107-sec-0030"></div> <section id="CD008107-sec-0031"> <h3 class="title" id="CD008107-sec-0031">Description of the condition</h3> <p>The epidemiology of adenocarcinoma of the stomach, gastroesophageal (GE) junction, and esophagus ('gastroesophageal adenocarcinoma') has changed in recent years. Incidence and mortality figures for cancers of the distal stomach have decreased in most countries whereas corresponding figures for adenocarcinoma of the esophagus and gastroesophageal junction have risen (<a href="./references#CD008107-bbs2-0038" title="FerlayJ , ShinHR , BrayF , FormanD , MathersC , ParkinDM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer2010;127(12):2893‐917. ">Ferlay 2010</a>; <a href="./references#CD008107-bbs2-0073" title="VialM , GrandeL , PeraM . Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results in Cancer Research2010;182:1‐17. ">Vial 2010</a>). Combined, gastroesophageal adenocarcinoma ranks among the most common cancers worldwide with an estimated toll of approximately 1,000,000 deaths per year (<a href="./references#CD008107-bbs2-0032" title="DeMeesterSR . Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Annals of Surgical Oncology2006;13(1):12‐30. ">DeMeester 2006</a>; <a href="./references#CD008107-bbs2-0038" title="FerlayJ , ShinHR , BrayF , FormanD , MathersC , ParkinDM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer2010;127(12):2893‐917. ">Ferlay 2010</a>; <a href="./references#CD008107-bbs2-0040" title="FormanD , BurleyVJ . Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Practice and Research. Clinical Gastroenterology2006;20(4):633‐49. ">Forman 2006</a>; <a href="./references#CD008107-bbs2-0041" title="GalloA , ChaC . Updates on esophageal and gastric cancers. World Journal of Gastroenterology2006;12(20):3237‐42. ">Gallo 2006</a>). </p> <p>Although differences in risk factors, gene expression, and tumor biology exist between adenocarcinoma of the stomach, gastroesophageal junction, and esophagus (<a href="./references#CD008107-bbs2-0047" title="MarsmanWA , TytgatGN , TenKateFJ , vanLanschotJJ . Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. Journal of Surgical Oncology2005;92(3):160‐8. ">Marsman 2005</a>; <a href="./references#CD008107-bbs2-0061" title="ShahMA , KhaninR , TangL , JanjigianYY , KlimstraDS , GerdesH , et al. Molecular classification of gastric cancer: a new paradigm. Clinical Cancer Research2011;17(9):2693‐701. [PUBMED: 21430069] ">Shah 2011</a>), they are often regarded as one entity and conveniently treated alike in metastatic or non‐resectable stages. In fact, an analysis on a large number of patients showed that the degree of efficacy of chemotherapy does not differ for tumors of different origin in this setting (<a href="./references#CD008107-bbs2-0031" title="ChauI , NormanAR , CunninghamD , OatesJ , HawkinsR , IvesonT , et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago‐gastric junction and gastric adenocarcinoma‐‐individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology2009;20(5):885‐91. ">Chau 2009</a>). Radical surgery is the only curative treatment modality for gastroesophageal adenocarcinoma. Depending on the exact tumor localization, distal or total gastrectomy, or esophagectomy with radical lymph node dissection, needs to be performed (<a href="./references#CD008107-bbs2-0047" title="MarsmanWA , TytgatGN , TenKateFJ , vanLanschotJJ . Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. Journal of Surgical Oncology2005;92(3):160‐8. ">Marsman 2005</a>). Despite the fact that surgical techniques and perioperative management have substantially improved over the last decades (<a href="./references#CD008107-bbs2-0032" title="DeMeesterSR . Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Annals of Surgical Oncology2006;13(1):12‐30. ">DeMeester 2006</a>; <a href="./references#CD008107-bbs2-0041" title="GalloA , ChaC . Updates on esophageal and gastric cancers. World Journal of Gastroenterology2006;12(20):3237‐42. ">Gallo 2006</a>), five‐year survival after curatively intended resection is only 20% to 30% for patients with locally advanced disease (<a href="./references#CD008107-bbs2-0042" title="HagenJA , DeMeesterSR , PetersJH , ChandrasomaP , DeMeesterTR . Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Annals of Surgery2001;234(4):520‐30. ">Hagen 2001</a>; <a href="./references#CD008107-bbs2-0063" title="SiewertJR , BottcherK , SteinHJ , RoderJD . Relevant prognostic factors in gastric cancer: ten‐year results of the German Gastric Cancer Study. Annals of Surgery1998;228(4):449‐61. ">Siewert 1998</a>). </p> </section> <section id="CD008107-sec-0032"> <h3 class="title" id="CD008107-sec-0032">Description of the intervention</h3> <p>Until recently, the standard treatment for gastroesophageal adenocarcinoma has been primary surgery; i.e. resection without prior tumor‐specific therapy. In light of poor survival rates (<a href="./references#CD008107-bbs2-0042" title="HagenJA , DeMeesterSR , PetersJH , ChandrasomaP , DeMeesterTR . Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Annals of Surgery2001;234(4):520‐30. ">Hagen 2001</a>; <a href="./references#CD008107-bbs2-0063" title="SiewertJR , BottcherK , SteinHJ , RoderJD . Relevant prognostic factors in gastric cancer: ten‐year results of the German Gastric Cancer Study. Annals of Surgery1998;228(4):449‐61. ">Siewert 1998</a>), there has been a strong rationale to design new treatment modalities in order to achieve better outcomes for patients with non‐metastatic tumors, especially for those with locally advanced disease at diagnosis. Perioperative chemotherapy, defined as chemotherapy before and, optionally, after surgery, is one approach aiming to increase overall and disease‐free survival of patients. Based on promising results from phase II studies (<a href="./references#CD008107-bbs2-0023" title="AjaniJA , MansfieldPF , OtaDM . Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World Journal of Surgery1995;19(2):216‐20. ">Ajani 1995</a>; <a href="./references#CD008107-bbs2-0044" title="KelsenDP . Adjuvant and neoadjuvant therapy for gastric cancer. Seminars in Oncology1996;23(3):379‐89. ">Kelsen 1996</a>; <a href="./references#CD008107-bbs2-0050" title="OttK , SendlerA , BeckerK , DittlerHJ , HelmbergerH , BuschR , et al. Neoadjuvant chemotherapy with cisplatin, 5‐FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer2003;6(3):159‐67. ">Ott 2003</a>) it has been tested in several randomized controlled trials. </p> </section> <section id="CD008107-sec-0033"> <h3 class="title" id="CD008107-sec-0033">How the intervention might work</h3> <p>There are several proposed mechanisms for how perioperative chemotherapy might improve outcomes. A higher likelihood of tumor‐free resection margins due to preoperative down‐staging of the tumor, the elimination of micrometastases before and directly after surgery, and the rapid preoperative improvement of tumor‐related symptoms which leads to better tolerability of the upcoming large surgical intervention might all contribute to higher overall and disease‐free survival (<a href="./references#CD008107-bbs2-0037" title="EguchiT , KoderaY , NakanishiH , YokoyamaH , OhashiN , ItoY , et al. The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo2008;22(6):707‐12. [PUBMED: 19180995] ">Eguchi 2008</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>). One concern when administering perioperative chemotherapy is the potentially higher level of treatment‐related morbidity and mortality due to cytotoxic effects, which might be particularly hazardous during and directly after surgical procedures. Most phase II trials have shown that the applied chemotherapeutic regimens have acceptable morbidity and mortality (<a href="./references#CD008107-bbs2-0023" title="AjaniJA , MansfieldPF , OtaDM . Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World Journal of Surgery1995;19(2):216‐20. ">Ajani 1995</a>; <a href="./references#CD008107-bbs2-0044" title="KelsenDP . Adjuvant and neoadjuvant therapy for gastric cancer. Seminars in Oncology1996;23(3):379‐89. ">Kelsen 1996</a>), but there have been reports of substantial adverse effects of certain regimens of cytotoxic drugs (<a href="./references#CD008107-bbs2-0022" title="AjaniJA , MayerRJ , OtaDM , SteeleGD , EvansD , RohM , et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. Journal of the National Cancer Institute1993;85(22):1839‐44. ">Ajani 1993</a>). </p> </section> <section id="CD008107-sec-0034"> <h3 class="title" id="CD008107-sec-0034">Why it is important to do this review</h3> <p>The evidence regarding the effect of perioperative chemotherapy on survival of patients with gastroesophageal adenocarcinoma is conflicting, with inconclusive results reported from trials (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>; <a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>; <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>; <a href="./references#CD008107-bbs2-0013" title="WangXL , WuGX , ZhangMD , GuoM , ZhangH , SunXF . A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports2000;7(2):241‐4. ">Wang 2000</a>; <a href="./references#CD008107-bbs2-0014" title="ZhaoWH , WangSF , DingW , ShengJM , MaZM , TengLS , et al. Apoptosis induced by preoperative oral 5'‐DFUR administration in gastric adenocarcinoma and its mechanism of action. World Journal of Gastroenterology2006;12(9):1356‐61. ">Zhao 2006</a>). Several recent systematic reviews aimed to summarize the available evidence. </p> <p>A prior Cochrane Review, published in 2007, assessed perioperative chemotherapy for gastric adenocarcinoma by performing a meta‐analysis (<a href="./references#CD008107-bbs2-0076" title="WuAW , XuGW , WangHY , JiJF , TangJL . WITHDRAWN: Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005047.pub3] ">Wu 2007</a>). The authors did not find significant differences in survival between patients treated with perioperative chemotherapy and those directly operated. However, the review excluded studies in which patients had received additional postoperative chemotherapy and studies comprising patients with adenocarcinoma of the esophagus. Thus, the number of included trials was limited to only four. Furthermore, after the authors carried out their literature search in mid‐2005, the results of three large randomized controlled trials (RCTs) (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>), of which two showed significant survival benefits for perioperative chemotherapy, have been published. The review has meanwhile been withdrawn for methodological reasons. </p> <p>A meta‐analysis published in 2004 included trials and previous meta‐analyses on patients with thoracic esophageal carcinoma of both histologies. It compared various neoadjuvant and adjuvant modalities, amongst which were perioperative chemotherapy and chemoradiotherapy, and found no survival advantage for perioperative chemotherapy alone and for perioperative chemoradiotherapy at one and two years postoperatively. A modest survival benefit for perioperative chemoradiotherapy was found at three years postoperatively. However, no subgroup analyses for the different histologies were conducted (<a href="./references#CD008107-bbs2-0046" title="MalthanerRA , WongRK , RumbleRB , ZurawL . Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta‐analysis. BMC Medicine2004;2:35. ">Malthaner 2004</a>). A Cochrane Review, which was updated in 2006, included 11 RCTs comparing perioperative chemotherapy with surgery alone for esophageal carcinoma of any histology. The authors concluded that the results suggested that perioperative chemotherapy may prolong survival, but judged the evidence to be inconclusive. Like the previous review, no subgroup analyses according to histological subtype were conducted (<a href="./references#CD008107-bbs2-0074" title="VogtK , FenlonD , RhodesS , MalthanerR . Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD001556.pub2] ">Vogt 2006</a>). Another systematic review with meta‐analysis, relying on individual patient data (IPD) from trials including patients with carcinoma of the esophagus and gastroesophageal junction, was published as an abstract only (<a href="./references#CD008107-bbs2-0069" title="ThirionPG , MichielsS , LeMaîtreA , TierneyJ , on behalf of the MetaAnalysis of Chemotherapy in Esophagus Cancer Collaborative Group. Individual patient data‐based meta‐analysis assessing pre‐operative chemotherapy in resectable oesophageal carcinoma. Journal of Clinical Oncology2007;25(18S):4512. ">Thirion 2007</a>). The authors reported a modest but significant benefit in terms of overall survival for perioperative chemotherapy. A subgroup analysis showed that this benefit was independent of histological subtype, and significant also in the subgroup of patients with adenocarcinoma, which comprised 46% of all included patients. The same group conducted an IPD meta‐analysis comparing perioperative chemoradiotherapy with surgery alone for esophageal carcinoma. Results were published as an abstract only (<a href="./references#CD008107-bbs2-0070" title="ThirionP , MaillardE , PignonJ . Individual patient data‐based meta‐analysis assessing the effect of preoperative chemo‐radiotherapy in resectable oesophageal carcinoma. International Journal of Radiation Oncology, Biology, Physics. Elsevier Science Inc., 2008; Vol. 72, issue 1:S71‐2. ">Thirion 2008</a>). A survival benefit for chemoradiotherapy was found independently of histological subtype, but patients with adenocarcinoma constituted only 33% of the trial populations. </p> <p>Lastly, a recently published update of a systematic review with meta‐analysis included RCTs comparing both perioperative chemotherapy and chemoradiotherapy with primary surgery in patients with esophageal cancer of both histologies (<a href="./references#CD008107-bbs2-0064" title="SjoquistKM , BurmeisterBH , SmithersBM , ZalcbergJR , SimesRJ , BarbourA , et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta‐analysis. Lancet Oncology2011;7:681‐92. ">Sjoquist 2011</a>). The analysis did not include patients with gastric adenocarcinoma. It showed a significant survival benefit for both perioperative modalities and in both histological subtypes with the exception of perioperative chemotherapy for squamous cell carcinoma, where the effect did not reach statistical significance. </p> <p>None of the cited analyses included data for all three tumor sites of gastroesophageal adenocarcinoma (esophagus, GE junction, stomach). Moreover, none of the analyses, mostly due to non‐availability of IPD, were able to sufficiently assess in subgroup and multivariable analyses the extent to which certain covariables such as patient and tumor characteristics might alter the treatment effect of perioperative chemotherapy. </p> <p>Therefore, we performed a new systematic comparison of perioperative chemotherapy with surgery alone for patients with locoregionally advanced resectable adenocarcinoma of the stomach, GE junction, and esophagus, including all three tumor sites and relying on IPD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008107-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008107-sec-0035"></div> <p>The primary objective of this systematic review was to assess if perioperative chemotherapy leads to a longer overall survival as compared to surgery without prior tumor‐specific therapy in patients with locoregionally advanced resectable adenocarcinoma of the stomach, GE junction, and esophagus. Secondary objectives are to compare disease‐free survival, resectability, tumor stage upon resection, perioperative morbidity, and mortality, and to assess the safety and toxicity of perioperative chemotherapy as well as reasons for possible non‐administration of the postoperatively planned cycles of chemotherapy where foreseen in the study protocol. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008107-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008107-sec-0036"></div> <section id="CD008107-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008107-sec-0038"> <h4 class="title">Types of studies</h4> <p>The review included only RCTs. Due to the specific intervention under study, blinding and placebo treatment are technically and/or ethically difficult because the unavoidable delay of surgery in a study arm where subjects receive a 'neoadjuvant' placebo treatment would indubitably lead to a significant worsening of their survival. Therefore, we did not consider blinding and placebo treatment as criteria for inclusion or exclusion. </p> </section> <section id="CD008107-sec-0039"> <h4 class="title">Types of participants</h4> <p>To be included in the review, trials needed to be conducted on patients fulfilling the following criteria: </p> <p> <ul id="CD008107-list-0001"> <li> <p>histologically confirmed adenocarcinoma of the stomach, GE junction, or esophagus; for studies which include patients with both adenocarcinoma and other histological entities like squamous cell carcinoma, we sought to obtain IPD or aggregate measures (see below) relating to patients with adenocarcinoma only; </p> </li> <li> <p>previously untreated;</p> </li> <li> <p>locoregionally advanced (UICC stage Ib and higher for adenocarcinoma of the stomach, UICC stage II for adenocarcinoma of the esophagus (<a href="./references#CD008107-bbs2-0066" title="SobinLH , WittekindC , SobinLH , WittekindC . In: SobinLH , WittekindC editor(s). TNM Classification of Malignant Tumours (UICC). New York: Wiley‐Liss, 2002. ">Sobin 2002</a>)); </p> </li> <li> <p>resectable based on staging exams;</p> </li> <li> <p>absence of distant or peritoneal metastases.</p> </li> </ul> </p> </section> <section id="CD008107-sec-0040"> <h4 class="title">Types of interventions</h4> <p>The experimental intervention in the context of this systematic review was defined as surgery with curative intention combined with perioperative chemotherapy, defined as a treatment regimen with any kind of cytotoxic/antineoplastic drug or a combination of several of these drugs. To be regarded as perioperative, chemotherapy needed to be administered in a neoadjuvant (preoperative) setting and, optionally, in an additional adjuvant (postoperative) manner. We also included studies if patients received pre‐ or postoperative radiotherapy in addition to perioperative chemotherapy. We defined the control intervention as surgery with curative intention without any prior tumor‐specific therapy, and included patients undergoing any surgery with curative intention. </p> </section> <section id="CD008107-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD008107-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome was time to death measured in days from the date of randomization, based on an intention‐to‐treat analysis. If censored time‐to‐event data or adequate summary measures of time‐to‐event data were not available from the single trials, we used the vital status (alive or deceased) at the end of follow‐up. </p> </section> <section id="CD008107-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes were:</p> <p> <ul id="CD008107-list-0002"> <li> <p>disease‐free survival time, defined as the time from a 'landmark' six months after randomization until recurrence (local or distant) or death of any cause (the landmark method accounts for the difference in the timing of surgery between the two treatment groups, for details see <a href="#CD008107-sec-0058">Data synthesis</a>); </p> </li> <li> <p>presence of a tumor‐free resection margin, as assessed from the surgical specimen by a pathologist (dichotomous outcome yes/no); </p> </li> <li> <p>tumor stage at resection, as assessed from the surgical specimen according to the version of the UICC's TNM (T0‐4, N0‐3, M0‐1) classification (<a href="./references#CD008107-bbs2-0066" title="SobinLH , WittekindC , SobinLH , WittekindC . In: SobinLH , WittekindC editor(s). TNM Classification of Malignant Tumours (UICC). New York: Wiley‐Liss, 2002. ">Sobin 2002</a>) provided in the respective trial's IPD or aggregate data; </p> </li> <li> <p>safety of the perioperative chemotherapy regimen measured by toxicity according to the version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) provided in the respective trial's IPD or aggregate data; </p> </li> <li> <p>perioperative morbidity (measured by assessing how many of the following events occurred: anastomotic leakage, postoperative pneumonia, postoperative wound infection), and mortality (measured by assessing if a patient died during surgery or the consecutive hospital stay); </p> </li> <li> <p>the frequency and reason(s) for possible non‐administration of the postoperatively planned cycles of chemotherapy where foreseen in the study protocol (for the perioperative chemotherapy arms). </p> </li> </ul> </p> </section> </section> </section> <section id="CD008107-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008107-sec-0045"> <h4 class="title">Electronic searches</h4> <p>In September 2008, we performed a computerized literature search in:</p> <p> <ul id="CD008107-list-0003"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Review of Effectiveness (DARE), the Cochrane Database of Systematic Reviews (CDSR) from <i>The Cochrane Library</i> (3rd Quarter 2008); </p> </li> <li> <p>MEDLINE (1950 to 2008 Sept week 2) (<a href="./appendices#CD008107-sec-0100">Appendix 1</a>); </p> </li> <li> <p>EMBASE (1980 to week 38, 2008); and</p> </li> <li> <p>LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud) (up to September 2008). </p> </li> </ul> </p> <p>We limited our search to studies in humans. There were no language restrictions for either searching or trial inclusion. We combined the Cochrane highly sensitive search strategy for identifying randomized trials in MEDLINE, sensitivity‐maximizing version, Ovid format (<a href="./references#CD008107-bbs2-0043" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) with specific search terms to identify randomized controlled trials in MEDLINE (see <a href="./appendices#CD008107-sec-0100">Appendix 1</a>). </p> <p>We adapted the MEDLINE search strategy for use in the other databases searched. Moreover, we searched the following online databases of ongoing trials: </p> <p> <ul id="CD008107-list-0004"> <li> <p><a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; </p> </li> <li> <p><a href="http://www.centerwatch.com" target="_blank">www.centerwatch.com</a>; </p> </li> <li> <p><a href="http://www.cancer.gov/clinicaltrials/" target="_blank">www.cancer.gov/clinicaltrials</a>; </p> </li> <li> <p><a href="http://www.trialscentral.org" target="_blank">www.trialscentral.org</a>; </p> </li> <li> <p><a href="http://www.calgb.org" target="_blank">www.calgb.org</a>; </p> </li> <li> <p><a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>; </p> </li> <li> <p><a href="http://www.eortc.be" target="_blank">www.eortc.be</a>; </p> </li> <li> <p><a href="http://www.swog.org/Visitors/ClinicalTrials.asp" target="_blank">www.swog.org/Visitors/ClinicalTrials.asp</a>; </p> </li> <li> <p><a href="http://www.ctg.queensu.ca" target="_blank">www.ctg.queensu.ca</a>. </p> </li> </ul> </p> <p>We extended our search using EMBASE, Ovid MEDLINE, and EBM Reviews ‐ Cochrane Central Register of Controlled Trials for studies published until 31 May 2011, which was the date when our database was closed for analysis (see <a href="#CD008107-sec-0055">Dealing with missing data</a>). </p> </section> <section id="CD008107-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We handsearched the abstracts from 1995 to 2008 of the American Digestive Disease Week (DDW) published in <i>Gastroenterology</i> , the United European Gastroenterology Week (UEGW) published in <i>Gut</i> and the Annual Meetings of the American Society of Clinical Oncology (ASCO) published in the <i>Journal of Clinical Oncology</i>. We scanned reference lists of retrieved articles to identify further relevant trials. We contacted experts in the field about any unpublished or ongoing studies. We asked the authors of trial reports published only as abstracts or of ongoing studies to contribute IPD or completed papers. </p> </section> </section> <section id="CD008107-sec-0047"> <h3 class="title" id="CD008107-sec-0047">Data collection and analysis</h3> <section id="CD008107-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two independent review authors (UR, TS) extracted the data. They assessed title, keywords, and abstracts of all studies retrieved with the search strategy described above. If, based on this information, the authors believed studies met the defined inclusion criteria, they retrieved and further assessed the full text and made a final decision on whether to include a trial. Arbitration of a third author, which was foreseen in cases where one author believed a specific trial met the inclusion criteria for the review whereas the other author did not, was not required. </p> </section> <section id="CD008107-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>The review authors used a standardized data extraction form to compile and document relevant facts on general trial characteristics, trial quality, patients' characteristics, interventions, and outcomes as specified above. This data extraction was performed independently. The data extraction form compiled the following items. </p> <p> <ul id="CD008107-list-0005"> <li> <p>General information on the trial: title, authors, contact address, funding sources, language, publication status, year of publication, place(s), and year(s) of trial conduction. </p> </li> <li> <p>Trial design issues: inclusion and exclusion criteria, randomization/quasi‐randomization, concealment of treatment allocation (adequate/unclear/inadequate/not used), length of trial/follow‐up period. </p> </li> <li> <p>Baseline characteristics of participants: size of intervention and comparison group and for each group the distribution of age, sex, comorbidity (measured, if given as World Health Organization (WHO) performance status or American Society of Anesthesiologists (ASA) classification), tumor location (esophagus, gastroesophageal junction, stomach), and tumor stage (TNM and UICC stage). </p> </li> <li> <p>Characteristics of the intervention: used chemotherapeutic/antineoplastic drugs, regimens (frequency of chemotherapy, timing in relation to the date of surgery, application mode, cumulative dose of chemotherapy planned and administered both pre‐ and postoperatively). </p> </li> <li> <p>Frequency of different types of surgery (approach, extent) performed in the intervention and control groups. </p> </li> <li> <p>Loss to follow‐up in each group.</p> </li> <li> <p>Outcomes in each group: hazard ratios (HRs) and confidence intervals (CIs) both for overall and, if available, disease‐free survival; number of events (death, disease recurrence) if HRs are not given; number of resections with tumor‐free margins; tumor stage at resection (TNM and UICC stage); toxicity according to CTCAE (number of grade 3/4 adverse events); hospital mortality; morbidity as the number of the following events combined: anastomotic leakage, postoperative pneumonia, postoperative wound infection. </p> </li> </ul> </p> <p>We pilot tested the data extraction form on five retrieved studies and slightly revised it. Two authors (UR, TS) performed data extraction independently. Consultation of a third author for arbitration, which was foreseen for cases where no consensus could be reached, was not required. </p> <section id="CD008107-sec-0050"> <h5 class="title">Individual patient data (IPD)</h5> <section id="CD008107-sec-0051"> <h6 class="title">Data requests</h6> <p>For each trial, we requested IPD from the respective trialists. The solicited variables were as follows: </p> <p> <ul id="CD008107-list-0006"> <li> <p>age at randomization</p> </li> <li> <p>sex</p> </li> <li> <p>histological type</p> </li> <li> <p>allocated treatment arm (intervention/control)</p> </li> <li> <p>date of randomization</p> </li> <li> <p>comorbidity (WHO/ECOG performance status)</p> </li> <li> <p>site of tumor (esophagus/GE junction/stomach)</p> </li> <li> <p>pretreatment tumor stage (TNM T stage)</p> </li> <li> <p>pretreatment nodal stage (TNM N stage)</p> </li> <li> <p>chemotherapy regimen received (protocol, alternative, none)</p> </li> <li> <p>date of surgery</p> </li> <li> <p>surgical approach</p> </li> <li> <p>extent of resection</p> </li> <li> <p>reasons no surgery undertaken</p> </li> <li> <p>postoperative death</p> </li> <li> <p>non‐fatal postoperative complications (type)</p> </li> <li> <p>toxicity of preoperative treatment (type, grade) </p> </li> <li> <p>tumor stage at resection (TNM yT stage)</p> </li> <li> <p>nodal status at resection (TNM yN stage)</p> </li> <li> <p>date of death or last visit</p> </li> <li> <p>vital status</p> </li> <li> <p>cause of death</p> </li> <li> <p>date of first recurrence</p> </li> <li> <p>date of progression</p> </li> <li> <p>nature of first failure (recurrence)</p> </li> <li> <p>lost to follow up (yes/no)</p> </li> </ul> </p> <p>We requested data for all randomized patients in the trial (intention‐to‐treat population). We solicited trialists to provide the most complete and updated follow‐up data which were available, even if the follow‐up was longer than that used for the pertinent publication. We entered data in a dedicated database. </p> </section> <section id="CD008107-sec-0052"> <h6 class="title">Quality control</h6> <p>We assessed the quality of the submitted IPD from the single trials in several ways.</p> <p> <ul id="CD008107-list-0007"> <li> <p>We compared the number of individual patient data sets with the intention‐to‐treat population reported in publications. We screened data sets for obvious duplicates or omissions (e.g. by checking patient IDs). </p> </li> <li> <p>We checked plausibility of the values supplied for each variable by looking for extreme outliers. </p> </li> <li> <p>We compared summary measures calculated from the data set with data reported in publications.</p> </li> <li> <p>We derived overall survival and disease‐free‐survival of the different treatment groups in each trial using the Kaplan‐Meier method and standard Cox regression analysis and compared with published survival estimates. </p> </li> <li> <p>We checked completeness and equality of follow‐up in the two trial arms by plotting a 'reverse' Kaplan‐Meier curve considering censored patients as patients who incurred the outcome (<a href="./references#CD008107-bbs2-0068" title="StewartLA , ClarkeMJ . Practical methodology of meta‐analyses (overviews) using updated individual patient data. Statistics in Medicine1995;14:2057‐79. ">Stewart 1995</a>). In addition, for the 'reverse' Kaplan‐Meier curves we evaluated the median follow‐up time. </p> </li> </ul> </p> <p>We attempted to clarify and solve any detected inconsistencies with the respective trialists.  </p> </section> </section> </section> <section id="CD008107-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Both independent review authors assessed trial quality with regard to bias in the domains: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias. The assessing author stated the level of bias ('low'/'high'/'unclear') that was assumed for each item. Based on this assessment, the author assigned an overall level of risk of existing bias to each trial ('low' if 'low' bias was assumed for all items, 'moderate' if 'high' or 'unclear' bias was assumed for one or two items, 'high' if 'high' or 'unclear' bias was assumed for at least three items). We used this bias level as a measurement of the quality of each trial in sensitivity and subgroup analyses (see below). In cases where the two review authors came to different conclusions regarding the risk of bias in the single domains, a third author acted as an arbiter and a consensus was reached. Statements, e.g. quotations from publications, supporting the judgment of the authors were to be given and presented in a 'Risk of bias' table for each trial. </p> </section> <section id="CD008107-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <p>We measured the effect of the intervention on overall and disease‐free survival with hazard ratios (HR). If possible the HR was based on IPD. If IPD were not available we calculated the HR (i) from the published reports, using methods described in Parmar et al (<a href="./references#CD008107-bbs2-0052" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>) and Tierney et al (<a href="./references#CD008107-bbs2-0071" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>), (ii) from binary mortality data. For the latter method a relative risk based on vital status (alive or deceased) at the end of follow‐up and sample sizes was calculated and imputed in the corresponding section in RevMan. Where it was feasible, we used various methods to indirectly estimate the trial HR, to check its reliability. </p> <p>For each trial we estimated log HRs and the standard errors of log HR using the following methods (based on those reported by Parmar, Tierney, and Williamson; <a href="./references#CD008107-bbs2-0052" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD008107-bbs2-0071" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>; <a href="./references#CD008107-bbs2-0075" title="WilliamsonPR , SmithCT , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21(22):3337‐51. ">Williamson 2002</a>), listed in order of preference: </p> <p> <ol id="CD008107-list-0008"> <li> <p>HR and confidence interval calculated directly from IPD.</p> </li> <li> <p>O‐E and variance of the log hazard ratio: log hazard ratio and its standard error estimated directly. </p> </li> <li> <p>HR reported with confidence interval or log‐rank P value: standard error estimated from confidence interval or P value (confidence interval used if both available). This is the preferred indirect method since the HR is directly extracted and the standard error is estimated very accurately. </p> </li> <li> <p>Adjusted HR reported with confidence interval or Cox proportional hazards P value: standard error estimated from confidence interval or P value (confidence interval used if both available). This will generally give an estimate close to the unadjusted HR, but different studies adjust for different factors, and the choice of adjustment factors could be data‐driven, leading to bias. </p> </li> <li> <p>Numbers of events reported with log‐rank P value: HR estimated from numbers of events, standard error estimated from this estimated HR and P value. This gives a indirect estimate of the HR since all events are considered, but may not be close to the actual HR, particularly if the hazards are not proportional. </p> </li> <li> <p>Kaplan‐Meier survival curve.</p> </li> <li> <p>Actuarial rates at fixed follow‐up and log‐rank P value. This gives an estimate of the HR similar to that of method (3), but only events up to the fixed follow‐up time are considered. </p> </li> </ol> </p> <p>For the effect of the intervention on disease‐free survival we calculated the HRs using these methods in their listed order of preference but for a landmark time of six months after date of randomization (for details see <a href="#CD008107-sec-0058">Data synthesis</a>). This landmark analysis accounts for the difference in the timing of surgery between the two treatment groups. </p> <p>We measured the intervention's effect on the presence of tumor‐free resection margins, a binary outcome, with an odds ratio (OR). We treated tumor stage upon resection as binary data by dichotomizing T stage (1/2 versus 3/4) and N stage (0 versus 1/2), and calculating ORs. We measured the intervention's toxicity by the total number of CTCAE grade 3/4 adverse events as well as of the single events. We compared postoperative mortality as well as postoperative morbidity, measured as the number of events specified above, by calculating risk differences. </p> </section> <section id="CD008107-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>We performed analyses with the results of the intention‐to‐treat analysis if provided in the single studies. For missing data, we tried to contact the authors of the single studies and asked them for the specific values. </p> <p>Our database was closed on 31 May 2011. Any data not available at that date, either because it was not provided by the trialists as IPD or because results of the respective trial had not been published as full manuscripts, were not included in our analyses. </p> </section> <section id="CD008107-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity clinically (by the judgment of the two independent review authors), as well as through the calculation of an I² statistic which is a measure for the percentage of the variability in effect estimates attributed to heterogeneity rather than sampling error. If heterogeneity between the effects found in single trials was shown to be too large, i.e. relevant clinical differences or an I² of above 0.5, we did not do a pooled analysis including all trials. </p> </section> <section id="CD008107-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>To assess possible publication bias, if the number of included studies was sufficient, we created a funnel plot using the different outcomes and evaluated funnel asymmetry with Begg's and Egger's tests (<a href="./references#CD008107-bbs2-0027" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088‐101. ">Begg 1994</a>; <a href="./references#CD008107-bbs2-0036" title="EggerM , DaveySG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>) with respect to continuous data or Peters' test (<a href="./references#CD008107-bbs2-0053" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Comparison of two methods to detect publication bias in meta‐analysis. JAMA2006;295:676–80. ">Peters 2006</a>) with respect to binary data. </p> </section> <section id="CD008107-sec-0058"> <h4 class="title">Data synthesis</h4> <p>For all outcomes, we combined IPD and aggregate data, according to availability from the single studies, using the two‐stage method (<a href="./references#CD008107-bbs2-0057" title="RileyRD , SimmondsMC , LookMP . Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. Journal of Clinical Epidemiology2007;60:431‐9. ">Riley 2007</a>). This implies that from those studies for which IPD were available, we calculated the outcome measure, as defined above, from the provided data. For studies where IPD were not available, we used the aggregate outcome measure derived from the pertinent publication. If for a given outcome a summary measure was not available from either IPD or publications, the respective trial was not included in the analysis of that endpoint. </p> <p>We performed data synthesis with results based on intention‐to‐treat analysis if available for the single studies. The estimated log HRs were combined using the generic inverse‐variance method, the result of which is presented as pooled HR with 95% confidence intervals on a logarithmic scale. The pooled HR represents the overall risk of an event for perioperative chemotherapy versus surgery alone. We calculated absolute effects on survival from the proportion of event‐free patients in the control group and the estimated HR (exp[ln(proportion event free)xHR]). We used a random‐effects model for all meta‐analyses. The usage of a random‐effects model was preferred to that of a fixed‐effect model because we assumed the existence of non‐explainable heterogeneity between the 'true' effects of the different treatment regimens implied in the studies. However, we re‐calculated all analyses with a fixed‐effect model in order to detect potential differences due to the methodological approach. In all tests of significance we calculated a two‐sided P value. </p> <p>For the secondary outcome disease‐free survival, we only pooled the HRs of those trials which provided disease‐free survival calculated from a landmark time of six months from randomization, either obtained by IPD or by aggregated data. In this analysis, recurrence (local and distant) and death occurring within six months of randomization were regarded as events at this landmark time, thus defining the respective patient's disease‐free survival as zero. Likewise, analyzing IPD, patients discovered to be never disease‐free during the first six months after randomization (including patients with R2 resection, patients who were operated on without any resection performed, and patients who were not operated) were also regarded as events at this landmark time. </p> <p>In the analyses of the secondary outcomes postoperative morbidity and mortality, the denominator included only patients who underwent surgery. In the analyses of the secondary outcome tumor stage at resection (pT stage and pN stage), the denominator was formed by the ITT population of the respective trials in order to treat patients who were not resected as 'treatment failures', as they were analyzed in the group of the more unfavorable pT and pN stage). </p> <p>We performed analyses using Review Manager (<a href="./references#CD008107-bbs2-0056" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). We used the statistical software packages R and SAS (<a href="./references#CD008107-bbs2-0055" title="R Foundation for Statistical Computing. R. Version 2.11.0. Vienna: R Foundation for Statistical Computing, 2010. ">R 2010</a>; <a href="./references#CD008107-bbs2-0059" title="SAS Institute. SAS. Version 9.2 and 9.3. Cary, North Carolina: SAS Institute, 2008 and 2011. ">SAS 2011</a>) for additional analyses that could not be done with <a href="./references#CD008107-bbs2-0056" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>. </p> </section> <section id="CD008107-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For the primary outcome, we conducted subgroup analyses stratified for:</p> <p> <ul id="CD008107-list-0009"> <li> <p>tumor site (esophagus, GE junction, stomach); for stratifying patients according to tumor site, we used the definition from the single trial; either as variable in IPD databases or from a subgroup analysis in the respective publication; </p> </li> <li> <p>sequence of planned perioperative therapy in the intervention arm (preoperative only versus preoperative and postoperative combined); </p> </li> <li> <p>chemotherapeutic agents used in preoperative chemotherapy (platinum‐based non‐anthracycline regimens versus anthracycline‐based non‐platinum regimens versus regimens containing both platinum and anthracycline versus other regimens); </p> </li> <li> <p>regimens including radiotherapy versus chemotherapy‐only schemes</p> </li> <li> <p>performance status (PS 0 versus 1 versus 2 or higher);</p> </li> <li> <p>age upon randomization (&lt; 65 years, 65 to 75 years, &gt; 75 years);</p> </li> <li> <p>sex (male versus female).</p> </li> </ul> </p> <p>Other subgroup analyses were defined based on exploratory analyses of the available data. </p> <p>For trial‐specific subgroup analyses, such as those stratified according to sequence of perioperative therapy, chemotherapeutic agents and regimen, we calculated pooled HRs for every prespecified trial group. For patient‐specific subgroup analyses such as those stratified according to performance status, age, and sex, we undertook Cox regressions including the relevant treatment by subgroup interaction term within each trial and pooled the interaction coefficients across trials. For this PWT (pooling of within‐trial covariate interactions) approach we followed <a href="./references#CD008107-bbs2-0039" title="FisherDJ , CopasAJ , TierneyJF , ParmarMKB . A critical review of methods for the assessment of patient‐level interactions in individual participant data meta‐analysis of randomized trials, and guidance for practitioners. Journal of Clinical Epidemiology2011;64:949‐67. ">Fisher 2011</a> by assessing heterogeneity with I² statistics and reporting if the fixed‐effect and random‐effects results are consistent. </p> <p>All patients were included in the analyses as originally randomized in the respective trial (i.e. according to the intention‐to‐treat principle), regardless of whether they were analyzed in the trial publication. In cases where specific data were missing, the respective patients were excluded from the analysis. </p> <section id="CD008107-sec-0060"> <h5 class="title">Investigation of important covariates</h5> <p>In a second step, we combined data from all trials providing IPD for the primary outcome 'overall survival' in a Cox proportional hazards model for clustered data. We used a shared frailty model for incorporating the trial, which represents a cluster, as random‐effects. By this, we examined how the association of treatment with survival was altered when covariates were accounted for. The covariates accounted for were treated as fixed‐effect, the trial as random‐effects. The following covariates were considered: </p> <p> <ul id="CD008107-list-0010"> <li> <p>treatment (chemotherapy only, chemoradiotherapy, surgery alone);</p> </li> <li> <p>tumor site (esophagus, GE junction, stomach);</p> </li> <li> <p>T stage (0/1/2 versus 3/4);</p> </li> <li> <p>N stage (0 versus 1/2/3);</p> </li> <li> <p>performance status (PS 0/1 versus 2 or higher);</p> </li> <li> <p>age upon randomization (as continuous variable);</p> </li> <li> <p>sex.</p> </li> </ul> </p> </section> </section> <section id="CD008107-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>For all outcomes, we conducted sensitivity analyses based on the risk of bias assigned to studies as described in <a href="#CD008107-sec-0053">Assessment of risk of bias in included studies</a> (low, moderate, high). Furthermore, we compared results from aggregate data for the primary endpoint and the secondary endpoint disease‐free survival with results from pooled IPD (<a href="./references#CD008107-bbs2-0054" title="PignonJP , HillC . Meta‐analyses of randomised clinical trials in oncology. Lancet2001;2:475‐82. ">Pignon 2001</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008107-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008107-sec-0062"></div> <section id="CD008107-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD008107-sec-0064"> <h4 class="title">Results of the search</h4> <p>After excluding duplicates, the prespecified electronic search of literature databases yielded 5848 results. An additional two trials, for which final efficacy results were already available, were identified by manual searches in conference proceedings and reference lists. Full papers of these trials (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>) were published after our electronic search was conducted, but before our database was closed for analysis. </p> <p>The extension of the search until the closure date of our database, 31May 2011 (see <a href="#CD008107-sec-0045">Electronic searches</a>), yielded 1251 results after exclusion of duplicates. None of these were included in our analysis. One trial included only one patient with adenocarcinoma and was published only as conference abstract. One abstract was a duplicate of a fully published study included in our analysis (<a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>). We assessed the full‐text paper of one trial. It showed that this trial formally met our inclusion criteria. However, since patients received chemotherapy for a very short period immediately prior to surgery (starting 72 and 68 hours and finishing 8 and 19.5 hours before surgery, respectively), we decided not to include this trial in our analysis as such an unconventional scheme is highly doubtful to influence our primary outcome, overall survival. Two other trials were not included because the full‐text publications were either unavailable or available only in Chinese for which a possibility of translation was not available at the time of the literature search, and because from the abstracts it remained unclear if the trials included any patients with adenocarcinoma. One trial was not included in our analysis as it was only available as a conference abstract and because it included only seven patients with adenocarcinoma (see <a href="./references#CD008107-sec-0109" title="">Characteristics of excluded studies</a>). </p> <p>A summary of all searched, included, and excluded studies (PRISMA diagram) is given in <a href="#CD008107-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD008107-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008107-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008107-sec-0065"> <h4 class="title">Included studies</h4> <p>From the search results, we identified 14 RCTs (total number of patients in ITT populations analyzed for overall survival: n = 3034) meeting our inclusion criteria (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>; <a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>; <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>; <a href="./references#CD008107-bbs2-0013" title="WangXL , WuGX , ZhangMD , GuoM , ZhangH , SunXF . A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports2000;7(2):241‐4. ">Wang 2000</a>; <a href="./references#CD008107-bbs2-0014" title="ZhaoWH , WangSF , DingW , ShengJM , MaZM , TengLS , et al. Apoptosis induced by preoperative oral 5'‐DFUR administration in gastric adenocarcinoma and its mechanism of action. World Journal of Gastroenterology2006;12(9):1356‐61. ">Zhao 2006</a>). Five of the trials (total n = 1657) included both patients with adenocarcinoma and squamous cell carcinoma of the esophagus (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>). These trials comprised n = 612 patients with squamous cell carcinoma and n = 1045 patients with adenocarcinoma. Thus, the total number of patients with adenocarcinoma in all included trials was n = 2422. One trial was a three‐armed RCT comparing two different preoperative chemotherapy regimens with one control group not receiving chemotherapy (<a href="./references#CD008107-bbs2-0014" title="ZhaoWH , WangSF , DingW , ShengJM , MaZM , TengLS , et al. Apoptosis induced by preoperative oral 5'‐DFUR administration in gastric adenocarcinoma and its mechanism of action. World Journal of Gastroenterology2006;12(9):1356‐61. ">Zhao 2006</a>). For this trial (total n = 54) we combined the chemotherapy treatment arms into one (n = 34) and compared this combined treatment arm to the control group (n = 20). Consequently, our final analysis was based on data from n = 2422 patients. The 14 included RCTs were carried out between 1989 (first patient randomized) and 2004 (last patient randomized). The number of included patients per trial ranges from 42 (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>) to 533 (<a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>). Across all included trials, 2477 patients with adenocarcinoma had originally been randomized, out of which 25 (and an unknown number from <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>) could not be included in our meta‐analysis either because they were not included in the trial analysis presented in the respective publication or because they were not contained in the provided IPD data sets (for details see <a href="./references#CD008107-sec-0108" title="">Characteristics of included studies</a>). </p> <p>For all trials, data on the primary outcome, overall survival, were available either as HRs calculated from individual patient data (IPD) provided by the investigators (eight trials, n = 1049 patients), as HRs indirectly estimated from aggregate data presented in the original publications (three trials, n = 1207 patients), as HRs estimated from Kaplan‐Meier survival curves (one trial, n = 54 patients), or as HRs estimated from binary mortality data (two trials, n = 112 patients) (compare <a href="#CD008107-sec-0036">Methods</a>). For four trials including patients with both adenocarcinoma and squamous cell carcinoma (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>), HRs for the primary outcome were calculated for patients with adenocarcinoma based on IPD. For some secondary outcomes, data were not available from all included studies. Thus, respective analyses are based on a smaller number of studies (see <a href="#CD008107-sec-0070">Effects of interventions</a>).  </p> </section> <section id="CD008107-sec-0066"> <h4 class="title">Excluded studies</h4> <p><a href="./references#CD008107-bbs2-0019" title="MarietteC , SeitzJF , MaillardE , MornexF , ThomasPA , RaoulJ , et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. ASCO Meeting Abstracts2010;28(15 Suppl):4005. ">Mariette 2010</a> and <a href="./references#CD008107-bbs2-0021" title="vanHagenP , HulshofMCCM , vanLanschotJJB , SteyerbergEW , HenegouwenMI , WijnhovenBPL , et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine2012;366(22):2074‐84. ">van Hagen 2012</a> were published after closure of our database and were not included. </p> </section> </section> <section id="CD008107-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD008107-sec-0068"> <h4 class="title">Quality of single studies</h4> <p>Risk of bias was low in three studies, moderate in seven studies, and high in four studies (see <a href="#CD008107-fig-0002">Figure 2</a> and <a href="#CD008107-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008107-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgments about each risk of bias item for each included study." data-id="CD008107-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD008107-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD008107-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> </section> <section id="CD008107-sec-0069"> <h4 class="title">IPD quality </h4> <p> <ul id="CD008107-list-0011"> <li> <p><i>Number of patients in IPD data sets compared with the intention‐to‐treat population reported in publications.</i> </p> </li> </ul> </p> <p>The number of patients contained in IPD data sets were in all but one trial identical with the intention‐to‐treat population reported in the corresponding publications. Only in the data set belonging to <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a> was there one additional patient in the surgery alone treatment group. The first author of <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a> clarified this as a coding error in the data set the publication was based on. </p> <p> <ul id="CD008107-list-0012"> <li> <p><i>Extreme outliers?</i> </p> </li> </ul> </p> <p>We could not identify any extreme and implausible outliers in the IPD provided.</p> <p> <ul id="CD008107-list-0013"> <li> <p><i>Any deviations in summary measures calculated from IPD compared with data reported in publications.</i> </p> </li> </ul> </p> <p>We compared the number of patients in the different strata of tumor site, resection margin, T stage, N stage, performance status, median or mean age, age range, and sex between IPD and published data for the single studies: </p> <p><a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>: In the publication, data were only presented for the whole trial population (patients with both squamous cell carcinoma and adenocarcinoma); no separate data were available for patients with adenocarcinoma. </p> <p><a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>: In the IPD 23 patients in the perioperative chemo and 44 patients in the surgery alone group had nodal metastasis; in the publication 23 patients in the perioperative chemo and 45 patients in the surgery alone group had nodal metastasis. </p> <p><a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>: In the IPD 16 patients in the perioperative chemo and 19 patients in the surgery alone group had R0 resection; in the publication 18 patients in the perioperative chemo and 19 patients in the surgery alone group had R0 resection. </p> <p><a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>: In the publication, data were only presented for the whole trial population (patients with both squamous cell carcinoma and adenocarcinoma); no separate data were available for patients with adenocarcinoma. </p> <p><a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>: In the publication, data were only presented for the whole trial population (patients with both squamous cell carcinoma and adenocarcinoma); no separate data were available for patients with adenocarcinoma. </p> <p><a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>: In the publication, data were only presented for the whole trial population (patients with both squamous cell carcinoma and adenocarcinoma); no separate data were available for patients with adenocarcinoma. </p> <p><a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>: No differences between IPD and published data. </p> <p><a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>: No difference between IPD and published data with respect to tumor site, resection margin, performance status, mean age, age range, and sex. The aggregated data of T stage and N stage upon resection could not be directly compared between IPD and aggregate data, as the figures given in the publication were based on a different denominator. </p> <p> <ul id="CD008107-list-0014"> <li> <p><i>Deviations in overall survival and disease‐free‐survival of the different treatment groups in each trial (derived from IPD using Kaplan‐Meier method and standard Cox regression analysis) as compared with published survival estimates.</i> </p> </li> </ul> </p> <p>In <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>, an estimate of the hazard ratio and its standard error resulted in 1.52 (95% confidence interval 0.84 to 2.74) in favor of surgery alone using method 5 described in <a href="#CD008107-sec-0054">Measures of treatment effect</a>. The hazard ratio estimate based on the corresponding database was 1.40 (95% confidence interval 0.78 to 2.53). This discrepancy in the hazard ratios resulted from a longer follow‐up of the patients in the IPD data set compared to the data set used for analysis in the pertinent publication. </p> <p>The legend in <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>, Figure 4 B and D, was not correct. The label of the patients at risk would need to be swapped (confirmed by the authors). </p> <p>In <a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a> the estimated HRs and their 95% confidence intervals for the three tumor sites, esophagus, gastroesophageal junction, and stomach, based on the IPD differed from those given in Figure A1 in the corresponding publication. In a discussion with the authors it has been figured out that the discrepancies are due to the fact that the IPD has a longer follow‐up than the data the publication was based on. </p> <p> <ul id="CD008107-list-0015"> <li> <p><i>Completeness and equality of follow‐up in the two trial arms were checked by plotting a 'reverse' Kaplan‐Meier curve considering censored patients as patients who incurred the outcome (</i><a href="./references#CD008107-bbs2-0068" title="StewartLA , ClarkeMJ . Practical methodology of meta‐analyses (overviews) using updated individual patient data. Statistics in Medicine1995;14:2057‐79. ">Stewart 1995</a><i>). In addition, for the 'reverse' Kaplan‐Meier curves the median follow‐up time was evaluated.</i> </p> </li> </ul> </p> <p>For each trial with IPD the cumulative accrual rate was compared between the two treatment arms. No relevant differences occurred. By checking the completeness and equality of follow‐up in the two treatment arms by plotting the reverse Kaplan‐Meier curves (not shown here), again no relevant differences became obvious. <a href="#CD008107-tbl-0003">Table 1</a> summarizes the median potential follow‐up time for each trial with IPD. </p> <div class="table" id="CD008107-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Median potential follow‐up time* in years for each trial with IPD</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median potential follow‐up time in years (95% confidence interval)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urba 2001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 (6.3 to 10.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Walsh 2002</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.6 (12.2 to 16.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAMTX 2004</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (8.3 to 10.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TROG‐AGITG 2005</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (4.4 to 6.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG 8911 2007</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 (8.1 to 9.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CALGB 9781 2008</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1 (5.5 to 6.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC 40954 2010</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4 (4.0 to 4.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACCORD 07 2011</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7 (5.1 to 6.6)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Follow‐up time calculated according to <a href="./references#CD008107-bbs2-0060" title="SchemperM , SmithTL . A note on quantifying follow‐up in studies of failure time. Controlled Clinical Trials1996;17:343‐6. ">Schemper 1996</a>. <br/> <br/> IPD: individual patient data </p> </div> </div> </section> </section> <section id="CD008107-sec-0070"> <h3 class="title" id="CD008107-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD008107-tbl-0001"><b>Summary of findings for the main comparison</b> Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</a>; <a href="./full#CD008107-tbl-0002"><b>Summary of findings 2</b> Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</a> </p> <section id="CD008107-sec-0071"> <h4 class="title">Primary outcome (overall survival)</h4> <p>Overall survival was reported by all 14 included studies. The meta‐analysis (<a href="./references#CD008107-fig-0014" title="">Analysis 1.1</a>) yielded a pooled hazard ratio (HR) of 0.81 (95% confidence interval (CI) 0.73 to 0.89, P &lt; 0.0001) for patients who received preoperative chemotherapy or chemoradiotherapy as compared to those who underwent surgery alone. This corresponds to a relative increase in survival of 19%. The simple (non‐stratified) overall survival curves of perioperative chemotherapy plus surgery versus surgery alone showed an absolute improvement in survival of 9% at five years, increasing survival from 23% for patients undergoing primary surgery to 32% for patients receiving perioperative chemotherapy. The results of the single studies showed differences in the magnitude of the treatment effect, but the I² was 10% and the test for heterogeneity was not significant. HRs ranged from 0.45 for <a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a> to 1.40 for <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>. The latter, together with <a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>, were the only studies showing a trend towards longer overall survival in the surgery alone arm. The corresponding funnel plot (<a href="#CD008107-fig-0004">Figure 4</a>) suggests possible reporting bias, as there are two small positive studies, but no small negative studies published. Nevertheless, Begg's and Egger's test revealed no evidence for funnel plot asymmetry (Begg's test P = 0.96, Egger's test P = 0.68, trim and fill method HR 0.82 with 95% CI 0.73 to 0.91). </p> <div class="figure" id="CD008107-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Overall survival, outcome: 1.1 Hazard ratio plot for overall survival." data-id="CD008107-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Overall survival, outcome: 1.1 Hazard ratio plot for overall survival. </p> </div> </div> </div> <p>The pooled HR of 0.81 is mirrored in the cumulative survival curve, which shows a sustained survival advantage for patients in the preoperative chemotherapy arms, starting at about 18 months after treatment onset, and lasting as long as 10 years (<a href="#CD008107-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD008107-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Simple (non‐stratified) overall survival curves of perioperative chemotherapy plus surgery versus surgery alone (perioperative chemo: 372 events, 525 total; surgery alone: 405 events, 524 total; hazard ratio 0.80, 95% CI 0.69 to 0.93)." data-id="CD008107-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Simple (non‐stratified) overall survival curves of perioperative chemotherapy plus surgery versus surgery alone (perioperative chemo: 372 events, 525 total; surgery alone: 405 events, 524 total; hazard ratio 0.80, 95% CI 0.69 to 0.93). </p> </div> </div> </div> </section> <section id="CD008107-sec-0072"> <h4 class="title">Subgroup analyses</h4> <section id="CD008107-sec-0073"> <h5 class="title">Tumor site</h5> <p>Definitions of tumor sites differed between trials, but they were usually stratified into esophagus, cardia/gastroesophageal (GE) junction, and stomach. One trial (<a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>) included only patients with esophageal tumors. Five trials (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>) included patients with esophageal and GE junction tumors. One trial (<a href="./references#CD008107-bbs2-0013" title="WangXL , WuGX , ZhangMD , GuoM , ZhangH , SunXF . A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports2000;7(2):241‐4. ">Wang 2000</a>) included only patients with gastroesophageal junction tumors. Four studies (<a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>; <a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0013" title="WangXL , WuGX , ZhangMD , GuoM , ZhangH , SunXF . A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports2000;7(2):241‐4. ">Wang 2000</a>; <a href="./references#CD008107-bbs2-0014" title="ZhaoWH , WangSF , DingW , ShengJM , MaZM , TengLS , et al. Apoptosis induced by preoperative oral 5'‐DFUR administration in gastric adenocarcinoma and its mechanism of action. World Journal of Gastroenterology2006;12(9):1356‐61. ">Zhao 2006</a>) included only patients with gastric tumors. One trial (<a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>) included patients with gastric and GE junction tumors. Two studies (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>) included patients with all tumor sites. For <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>, site‐specific results were not presented in the publication, and IPD was not provided. For <a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a> and <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>, site‐specific results were available neither from publications nor from provided IPD, and thus these studies could not be included in the subgroup analyses for tumor site, which could be performed for the three tumor sites: esophagus, GE junction, and stomach, based on data from five, six, and seven studies, respectively (<a href="./references#CD008107-fig-0016" title="">Analysis 1.3</a>). The results showed a more pronounced survival advantage for perioperative chemotherapy in patients with tumors of the GE junction (pooled HR 0.69, 95% CI 0.54 to 0.87) compared to the esophagus (pooled HR 0.87, 95% CI 0.73 to 1.05), and stomach (pooled HR 0.94, 95% CI 0.82 to 1.06), but the interaction test did not reach statistical significance (P = 0.08). </p> <p>In this subgroup analysis the effect of trial characteristics and patient characteristics are mixed as some trials include only certain tumor sites. Therefore, we investigated the interaction between treatment and tumor site in those trials where this was possible, i.e. IPD trials (<a href="./references#CD008107-fig-0017" title="">Analysis 1.4</a>). The heterogeneity coefficient of I² = 4% was not significant. </p> </section> <section id="CD008107-sec-0074"> <h5 class="title">Sequence of planned perioperative therapy in the intervention arm</h5> <p>There were no relevant differences in the effect of preoperative chemotherapy on overall survival between the nine trials where only preoperative chemotherapy was stipulated and the five trials where both pre‐ and postoperative chemotherapy were foreseen (<a href="./references#CD008107-fig-0019" title="">Analysis 1.6</a>). However, it must be noted that even in the trials where postoperative chemotherapy was planned (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>; <a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>), only between 22% (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>) and 42% (<a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>) of patients received the full number of planned postoperative cycles (see below). </p> </section> <section id="CD008107-sec-0075"> <h5 class="title">Chemotherapeutic agents used in preoperative chemotherapy</h5> <p>Ten of the 14 included trials relied on a platinum‐based non‐anthracycline regimen. Therefore, this preplanned subgroup analysis was of limited value, as the other subgroups (anthracycline‐based non‐platinum regimens, regimens containing both platinum and anthracycline, and other regimens), consisted of one, one, and two trials. For platinum‐based non‐anthracycline regimens, the pooled HR was 0.80 (95% CI 0.72 to 0.89) and thus almost identical to the pooled HR of all included trials (<a href="./references#CD008107-fig-0020" title="">Analysis 1.7</a>). </p> </section> <section id="CD008107-sec-0076"> <h5 class="title">Regimens including radiotherapy versus chemotherapy only schemes</h5> <p>In 10 trials (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>; <a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>; <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0013" title="WangXL , WuGX , ZhangMD , GuoM , ZhangH , SunXF . A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports2000;7(2):241‐4. ">Wang 2000</a>; <a href="./references#CD008107-bbs2-0014" title="ZhaoWH , WangSF , DingW , ShengJM , MaZM , TengLS , et al. Apoptosis induced by preoperative oral 5'‐DFUR administration in gastric adenocarcinoma and its mechanism of action. World Journal of Gastroenterology2006;12(9):1356‐61. ">Zhao 2006</a>), the intervention arm stipulated a regimen which included chemotherapy only. In four trials (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>), the intervention was chemoradiotherapy (<a href="./references#CD008107-fig-0018" title="">Analysis 1.5</a>). All of the latter comprised exclusively patients with tumors of the esophagus or GE junction. Pooled subgroup analyses showed a significant benefit in terms of overall survival for both modalities. The magnitude of the effect was stronger for chemoradiotherapy, but the confidence interval of the pooled HR was wider due to the lower absolute number of participants in this subgroup. The interaction test was not significant. Of note, there was considerably higher heterogeneity among results of trials using chemoradiotherapy with the corresponding I² value just at the border of what we considered meaningful for a pooled analysis. </p> </section> <section id="CD008107-sec-0077"> <h5 class="title">Performance status</h5> <p>No publication provided sufficient information regarding overall survival stratified by performance status upon randomization. Two IPD data sets (<a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>) did not contain information on performance status. Five (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>) out of the six remaining IPD data sets measured performance status according to ECOG/WHO, whereas <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a> used the Karnofsky score. This was converted to the ECOG/WHO classification according to <a href="./references#CD008107-bbs2-0072" title="VergerE , SalameroM , ConillC . Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group Scoring Scale and vice‐versa. European Journal of Cancer1992;28A(8‐9):1328‐30. ">Verger 1992</a>. </p> <p>In all trials with data on performance status, only five patients with a performance status of 2 or higher were included. Thus, this small group was not included in the subgroup analysis. The treatment by performance status interaction effect estimates from each trial were consistent (I² = 0%, P = 0.90, τ² = 0; pooled interaction effect under REM and FEM 0.34 with 95% CI ‐0.03 to 0.71; <a href="./references#CD008107-fig-0022" title="">Analysis 1.9</a>). The within‐trial HRs for overall survival in each subgroup are presented in <a href="./references#CD008107-fig-0021" title="">Analysis 1.8</a> . </p> </section> <section id="CD008107-sec-0078"> <h5 class="title">Age</h5> <p>No publication provided sufficient information regarding overall survival stratified by age upon randomization. This information was however available in all IPD data sets. Only 16 patients with an age of more than 75 years were randomized in any of the included trials, which precluded analysis in that subgroup. There was no evidence of subgroup differences with respect to the treatment by age interaction effect estimates. The latter were consistent over all trials (I² = 9%, P = 0.36, τ² = 0.02; pooled interaction effect under REM ‐0.07 with 95% CI ‐0.40 to 0.26; pooled interaction effect under FEM ‐0.06 with 95% CI ‐0.37 to 0.24; <a href="./references#CD008107-fig-0024" title="">Analysis 1.11</a>). The within‐trial HRs for overall survival are presented in <a href="./references#CD008107-fig-0023" title="">Analysis 1.10</a>. </p> </section> <section id="CD008107-sec-0079"> <h5 class="title">Sex</h5> <p>No publication provided sufficient information regarding overall survival stratified by sex. This information was however available in all IPD data sets. About 83% of participants in the trials were male. Pooling of within‐trial covariate interactions revealed no subgroup difference between males and females (I² = 0%, P = 0.45, τ² = 0; pooled interaction effect under REM and FEM ‐0.18 with 95% CI ‐0.59 to 0.23; <a href="./references#CD008107-fig-0026" title="">Analysis 1.13</a>). The within‐trial HRs for overall survival are presented in <a href="./references#CD008107-fig-0025" title="">Analysis 1.12</a>. </p> </section> <section id="CD008107-sec-0080"> <h5 class="title">Pretreatment tumor stage</h5> <p>Post hoc subgroup analyses according to pretreatment T stage (T0/1/2 versus T3/4) and pretreatment N stage (N0 versus N1/2/3) were done for all IPD data sets with available information (<a href="./references#CD008107-fig-0027" title="">Analysis 1.14</a>; <a href="./references#CD008107-fig-0029" title="">Analysis 1.16</a>). Three (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>) out of eight trials with IPD provided information on pretreatment T stage but only one (<a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>) had included enough patients with pretreatment stage T3/4 to investigate an interaction between treatment and T stage (<a href="./references#CD008107-fig-0028" title="">Analysis 1.15</a>). Four trials provided information on pretreatment N stage (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>). Pooling of within‐trial covariate interactions revealed no subgroup difference between N0 and N1/2/3 (I² = 0%, P = 0.58, τ² = 0; pooled interaction effect under REM and FEM ‐0.02 with 95% CI ‐0.63 to 0.59; <a href="./references#CD008107-fig-0030" title="">Analysis 1.17</a>). </p> </section> <section id="CD008107-sec-0081"> <h5 class="title">Resection status</h5> <p>In order to assess the influence of resection status (R0/1/2) on survival, we conducted a pooled survival analysis with patients from both arms of all five trials for which respective data were available (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>)<i>.</i> A subgroup analysis according to resection status comparing overall survival for patients who received perioperative chemotherapy and those who underwent primary surgery was not appropriate, as the distribution of resection status was significantly different between treatment arms, probably because it was directly influenced by the treatment a patient received. For the same reason, the variable resection status was not included in the Cox model (see below). The Kaplan‐Meier curves show that resection status is a strong predictor for overall survival, with patients with R1 or R2 resection having a substantially poorer prognosis than patients with R0 resection (<a href="#CD008107-fig-0006">Figure 6</a>). Five‐year survival probabilities were 37% (95% CI 33% to 42%) in the R0 group, 7% (95% CI 0% to 15%) in the R1 group, and 0% in the R2 group. The corresponding HRs were 0.31 (95% CI 0.22 to 0.44) for R0 versus R1 and 0.18 (95% CI 0.25 to 0.13) for R0 versus R2. </p> <div class="figure" id="CD008107-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Overall survival curves by type of resection: 719 patients with R0, R1 or R2, 99 patients not resected or missing (R0: 390 events, 611 total; R1: 43 events, 46 total; R2: 60 events, 62 total)." data-id="CD008107-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Overall survival curves by type of resection: 719 patients with R0, R1 or R2, 99 patients not resected or missing (R0: 390 events, 611 total; R1: 43 events, 46 total; R2: 60 events, 62 total). </p> </div> </div> </div> </section> <section id="CD008107-sec-0082"> <h5 class="title">Sensitivity analyses</h5> <p>A sensitivity analysis which compared trials from which only aggregate data were available with those from which IPD were available revealed no differences, with both pooled HRs being almost identical (<a href="./references#CD008107-fig-0015" title="">Analysis 1.2</a>). A meta‐analysis excluding trials with high risk of bias yielded a HR of 0.82 (95% CI 0.72 to 0.93), which is virtually identical to the result of the meta‐analysis of all trials. A meta‐analysis including only the three trials with low risk of bias (424 patients) yielded a HR of 0.88 (95% CI 0.60 to 1.28). A meta‐analysis excluding the two trials from which only data on ‘vital status at end of follow‐up’ and no time‐to‐event data were available yielded a HR of 0.81 (95% CI 0.72 to 0.92). </p> </section> <section id="CD008107-sec-0083"> <h5 class="title">Investigation of important covariates</h5> <p>A Cox proportional hazards model without any covariates but the treatment arm chemo(radio)therapy versus surgery alone as fixed‐effect and trial as random‐effects applied to all eight IPD data sets summarized in a single database (with 1049 patients) resulted in a HR of 0.80 (95% CI 0.69 to 0.93; see also <a href="#CD008107-fig-0005">Figure 5</a>). </p> <p>Two (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>) out of eight trials with available IPD provided no information on exact tumor site (gastroesophageal junction or esophagus). For five (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>) out of eight trials with available IPD no information on pretreatment T stage was available, for four (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>) trials no information on pretreatment N stage was available. For two trials (<a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>) information on performance status was missing. As the imputation of a covariate for a whole trial data set (not just a few patients in a trial) was not reasonable, no imputation methods for missing data were used and analyses were only conducted as complete case analyses. </p> <p>In a first step, we analyzed the influence of each single prespecified covariate on the treatment effect of chemo(radio)therapy versus surgery alone by a Cox proportional hazards model with treatment and covariate as fixed‐effect and the trial as random‐effects based on all eligible patients (<a href="#CD008107-tbl-0004">Table 2</a>). The magnitude of the effect of perioperative chemo(radio)therapy on survival remained largely unchanged when adjusting for the separate covariates. </p> <div class="table" id="CD008107-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adjusted hazard ratio (HR) for the treatment effect (death for perioperative chemotherapy versus surgery alone) in a Cox proportional hazards model</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjustment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI))</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For tumor site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>931 (326 esophagus, 352 GE junction, 253 stomach)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.70 to 0.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0117</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For cT stage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (152 T0/1/2, 265 T3/4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.65 to 1.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1258</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For cN stage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453 (250 N0, 203 N1/2/3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.71 to 1.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3361</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For performance status</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>846 (595 PS 0, 251 PS 1/2/higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.73 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0651</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For age</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1049 (median 62, minimum 23, maximum 80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 (0.70 to 0.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0031</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For gender</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1049 (870 male, 179 female)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.69 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GE: gastroesophageal; PS: performance status</p> </div> </div> <p>In a second step, we did a complete case multivariable analysis with respect to the three treatment arms chemotherapy only, chemoradiotherapy, and surgery alone and all prespecified covariates except pretreatment T and N stage. For Cox proportional hazards regression analyses, we first tested the assumption of proportional hazards by plotting log(‐log(survival probability)) versus log of survival time stratified by treatment and by including time‐dependent covariables in the whole model. However, we detected no major violations of the proportional hazards assumption. Pretreatment T and N stage were not included as covariates because otherwise the complete case sample size would have dropped to 248. Only three patients had a performance status 2 or higher. Therefore, the Cox model deviated from the planned analysis by dichotomizing the performance status into 0 versus 1, 2, or higher. The results of the multivariable analysis based on 804 patients taking into account treatment arm, tumor site, performance class, age, and gender as covariates are summarized in <a href="#CD008107-tbl-0005">Table 3</a>. </p> <div class="table" id="CD008107-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Multivariable analysis: Cox proportional hazards model based on five trials* with 804 patients. Regression coefficients (β) with standard errors (SE) and hazard ratios (HR) for death with 95% confidence intervals (CI)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Univariable</b> </p> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multivariable</b> </p> <p><b>β (SE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multivariable</b> </p> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multivariable</b> </p> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment arm</p> <p>(chemotherapy only</p> <p>vs surgery alone)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>324 chemotherapy only,</p> <p>80 chemoradiotherapy,</p> <p>400 surgery alone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> <p>(0.70 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.16 (0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 <br/> (0.71 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0972</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment arm</p> <p>(chemoradiotherapy</p> <p>vs surgery alone)**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02</p> <p>(0.72 to 1.45)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (0.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99</p> <p>(0.69 to 1.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9351</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumor site</p> <p>(esophagus vs stomach)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>321 esophagus, <br/> 308 GE junction, <br/> 175 stomach </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.28</p> <p>(1.60 to 3.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.23 <br/> (1.55 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumor site</p> <p>(GE junction vs stomach)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> <p>(1.35 to 2.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56 (0.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.75</p> <p>(1.29 to 2.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0003</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance status</p> <p>(0 vs 1/2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>565 PS 0, <br/> 239 PS 1/2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> <p>(0.62 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.30 (0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> <p>(0.62 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0010</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age</p> <p>(continuous variable)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 61, <br/> Minimum 23, <br/> Maximum 81 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01</p> <p>(1.00 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (0.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (1.00 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0124</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gender</p> <p>(male vs female)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667 male, <br/> 137 female </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26</p> <p>(0.99 to 1.60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11 (0.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 (0.87 to 1.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3757</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a> </p> <p>**The group 'chemoradiotherapy' includes 80 patients from one single trial (<a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>) </p> <p>GE: gastroesophageal; PS: performance status</p> </div> </div> <p>After adjusting for the various covariates, the effect of perioperative chemotherapy on survival decreased slightly in magnitude and was no longer statistically significant. There seemed to be no effect of perioperative chemoradiotherapy on survival, but we were able to include only a single trial, which was negative, in the model (<a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>) whereas three positive trials (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>) could not be included due to unavailability of the variables required for the model. Tumor site, performance status, and age had a significant effect on survival even after multivariable adjustment. </p> <p>We investigated interactions between treatment and one covariate at a time in the multivariable Cox regression model. An interaction between treatment and age was significant (multivariable P = 0.0168, not shown in table). This suggests that age may play a role in whether perioperative chemotherapy is more effective than primary surgery. Including an interaction term between treatment and age in the multivariable analysis revealed a trend of an increasing HR with increasing age, with the confidence interval including 1 at age 60, and with the point estimate of the HR being larger than 1 at age 70. While younger patients had a more pronounced survival benefit for perioperative chemotherapy, the treatment effect seemed to decrease or even disappear in older patients (<a href="#CD008107-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD008107-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Hazard ratio with 95% confidence interval for perioperative chemo(radio)therapy versus surgery alone for age in 5‐year increments." data-id="CD008107-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Hazard ratio with 95% confidence interval for perioperative chemo(radio)therapy versus surgery alone for age in 5‐year increments. </p> </div> </div> </div> <p>Although an interaction between treatment and tumor site was not significant (multivariable P = 0.1346, not shown in table) we report the tumor site‐specific HRs for the treatment effect: esophagus HR 0.95 (95% CI 0.74 to 1.21), GE junction HR 0.73 (95% CI 0.55 to 0.95), stomach HR 1.15 (95% CI 0.76 to 1.73). The HR for patients with a resectable adenocarcinoma of the esophagus and of GE junction are less extreme in comparison to the forest plot (<a href="./references#CD008107-fig-0016" title="">Analysis 1.3</a>) whereas the HR for patients with a resectable adenocarcinoma of the stomach is reversed but does not reach statistical significance. </p> </section> </section> <section id="CD008107-sec-0084"> <h4 class="title">Secondary outcomes</h4> <section id="CD008107-sec-0085"> <h5 class="title">Disease‐free survival</h5> <p>As we chose to calculate disease‐free survival according to the 'landmark' method (see <a href="#CD008107-sec-0036">Methods</a>) and, with the exception of <a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>, no publication included the respective results, we could conduct this analysis exclusively for studies for which IPD were provided. However, the information in one IPD data set (<a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>) was not sufficient to use the landmark method as data on disease‐free survival were not provided. Thus, our landmark analysis of disease‐free survival is based on seven studies comprising 931 patients (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>). The results (<a href="./references#CD008107-fig-0031" title="">Analysis 2.1</a>) resemble those of the pooled analysis of overall survival, with very small differences between HRs for overall and disease‐free survival. The pooled HR for disease‐free survival is 0.84 (95% CI 0.69 to 1.01) and thus slightly higher than for overall survival, and no statistical significance is reached (P = 0.06). Given the relatively small number of included trials, the corresponding funnel plot (<a href="#CD008107-fig-0008">Figure 8</a>) is difficult to interpret, but does not suggest publication bias (Begg's test P = 0.88, Egger's test P = 0.92, trim and fill method added no studies). </p> <div class="figure" id="CD008107-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Disease‐free survival (landmark time 6 months), outcome: 2.1 Hazard ratio plot for disease‐free survival (landmark time 6 months)." data-id="CD008107-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Disease‐free survival (landmark time 6 months), outcome: 2.1 Hazard ratio plot for disease‐free survival (landmark time 6 months). </p> </div> </div> </div> <p>As only studies with IPD were able to provide data for the meta‐analysis of disease‐free survival we could not perform a sensitivity analysis comparing trials with and without available IPD. None of the seven trials used in the meta‐analysis had a high risk of bias. When excluding the three trials with moderate risk of bias, the magnitude of the effect found in the meta‐analysis remained largely unchanged with a HR of 0.85 (95% CI 0.57 to 1.27). </p> </section> <section id="CD008107-sec-0086"> <h5 class="title">Presence of tumor‐free resection margin</h5> <p>Data on the presence of a tumor‐free resection margin were available from 10 studies (<a href="./references#CD008107-fig-0032" title="">Analysis 3.1</a>). The meta‐analysis showed a higher likelihood of tumor‐free resection margin in patients who had received perioperative chemotherapy, but the association was just not statistically significant (odds ratio (OR) 1.29; 95% CI 1.04 to 1.60). There was heterogeneity between the single studies (I² = 55%). The corresponding funnel plot (<a href="#CD008107-fig-0009">Figure 9</a>) did not suggest relevant publication bias (Peters' test P = 0.75, trim and fill method: OR 1.22; 95% CI 0.82 to 1.82). </p> <div class="figure" id="CD008107-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Presence of tumor‐free resection margin, outcome: 3.1 Odds ratio plot for tumor‐free resection margin." data-id="CD008107-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Presence of tumor‐free resection margin, outcome: 3.1 Odds ratio plot for tumor‐free resection margin. </p> </div> </div> </div> <p>The sensitivity analysis showed an OR of 1.53 (95% CI 1.05 to 2.23) when excluding two trials with high risk of bias, and of 1.69 (95% CI 0.98 to 2.93) when excluding another five trials with moderate risk of bias. </p> </section> <section id="CD008107-sec-0087"> <h5 class="title">Tumor stage at resection</h5> <p>Data on T stage upon resection were available from seven studies (<a href="./references#CD008107-fig-0033" title="">Analysis 4.1</a>). The meta‐analysis showed that a T0/1/2 stage was significantly more frequent in patients who had received perioperative chemotherapy than in those who underwent surgery alone (OR 1.53; 95% CI 1.02 to 2.31). There was heterogeneity between results of the single studies, but all except two studies (<a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>) showed a higher frequency of T0/1/2 stages in the perioperative chemotherapy group. The corresponding funnel plot (<a href="#CD008107-fig-0010">Figure 10</a>) did not suggest relevant publication bias (Peters' test P = 0.45, trim and fill method added no studies). </p> <div class="figure" id="CD008107-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 4 Tumor stage at resection, outcome: 4.1 Odds ratio plot for tumor stage T0/T1/T2." data-id="CD008107-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 4 Tumor stage at resection, outcome: 4.1 Odds ratio plot for tumor stage T0/T1/T2. </p> </div> </div> </div> <p>The sensitivity analysis showed an OR of 1.69 (95% CI 1.08 to 2.66) when excluding one trial with high risk of bias, and of 1.69 (95% CI 1.13 to 2.52) when excluding another three trials with moderate risk of bias. </p> <p>Data on N stage upon resection were available from eight studies (<a href="./references#CD008107-fig-0034" title="">Analysis 4.2</a>). The meta‐analysis showed that a N0 stage was significantly more frequent in patients who had received perioperative chemotherapy (OR 2.00; 95% CI 1.58 to 2.55). There was considerable heterogeneity between results of the single studies (I² = 71%), with an OR as high as 23.4 in <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>. All but one trial showed a higher frequency of an N0 stage in the intervention group. The corresponding funnel plot (<a href="#CD008107-fig-0011">Figure 11</a>) suggested publication bias as the trim and fill method added three studies in the opposite direction of <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>, <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a> and <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>, and resulted in a considerably lower OR (Peters' test P = 0.04, trim and fill method: OR 1.62; 95% CI 0.95 to 2.74). </p> <div class="figure" id="CD008107-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 4 Tumor stage at resection, outcome: 4.2 Odds ratio plot for nodal status N0." data-id="CD008107-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 4 Tumor stage at resection, outcome: 4.2 Odds ratio plot for nodal status N0. </p> </div> </div> </div> <p>The sensitivity analysis showed an OR of 2.38 (95% CI 1.51 to 3.74) when excluding five trials with moderate risk of bias. </p> </section> <section id="CD008107-sec-0088"> <h5 class="title">Postoperative morbidity</h5> <p>Data on postoperative morbidity were available from nine studies (<a href="./references#CD008107-fig-0036" title="">Analysis 6.1</a>). There was considerable variation in absolute reported morbidity between the single studies with rates in the single arms ranging from 0% (<a href="./references#CD008107-bbs2-0013" title="WangXL , WuGX , ZhangMD , GuoM , ZhangH , SunXF . A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports2000;7(2):241‐4. ">Wang 2000</a>, both arms) to 63% (<a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>, primary surgery arm). The meta‐analysis did not show any significant differences in postoperative morbidity between trial arms (risk difference 0.01; 95% CI ‐0.03 to 0.05). There was no relevant heterogeneity between results of the single studies and all confidence intervals included equity. The corresponding funnel plot (<a href="#CD008107-fig-0012">Figure 12</a>) did not suggest relevant publication bias (Peters' test P = 0.93, trim and fill method added no studies). </p> <div class="figure" id="CD008107-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Postoperative morbidity, outcome: 6.1 Risk difference plot for postoperative morbidity." data-id="CD008107-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Postoperative morbidity, outcome: 6.1 Risk difference plot for postoperative morbidity. </p> </div> </div> </div> <p>The sensitivity analysis showed an absolute risk difference of 0.02 (95% CI ‐0.03 to 0.07) when excluding three trials with high risk of bias, and of 0.04 (95% CI ‐0.07 to 0.15) when excluding another three trials with moderate risk of bias. </p> </section> <section id="CD008107-sec-0089"> <h5 class="title">Postoperative mortality</h5> <p>Data on postoperative mortality were available from 11 studies (<a href="./references#CD008107-fig-0037" title="">Analysis 7.1</a>). Overall, mortality rates ranged between 0% (<a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0013" title="WangXL , WuGX , ZhangMD , GuoM , ZhangH , SunXF . A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports2000;7(2):241‐4. ">Wang 2000</a>; <a href="./references#CD008107-bbs2-0014" title="ZhaoWH , WangSF , DingW , ShengJM , MaZM , TengLS , et al. Apoptosis induced by preoperative oral 5'‐DFUR administration in gastric adenocarcinoma and its mechanism of action. World Journal of Gastroenterology2006;12(9):1356‐61. ">Zhao 2006</a>, both arms) and 7.4% (<a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>, perioperative chemotherapy arm) in the single trial arms. The meta‐analysis did not show any significant differences in postoperative mortality between trial arms (risk difference 0.00; 95% CI ‐0.01 to 0.02). There was no relevant heterogeneity between results of the single studies, and all confidence intervals included equity. The corresponding funnel plot (<a href="#CD008107-fig-0013">Figure 13</a>) suggested a relevant publication bias, although the trim and fill method added only one trial with no relevant change in the overall risk difference (Peters' test P &lt; 0.001, trim and fill method: RD 0.00 with 95% CI ‐0.01 to 0.02). </p> <div class="figure" id="CD008107-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 7 Postoperative mortality, outcome: 7.1 Risk difference plot for postoperative mortality." data-id="CD008107-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 7 Postoperative mortality, outcome: 7.1 Risk difference plot for postoperative mortality. </p> </div> </div> </div> <p>The sensitivity analysis showed an absolute risk difference of 0.00 (95% CI ‐0.01 to 0.02) when excluding three trials with high risk of bias, and of 0.02 (95% CI ‐0.02 to 0.05) when excluding another five trials with moderate risk of bias. </p> </section> <section id="CD008107-sec-0090"> <h5 class="title">Safety</h5> <p>Data on the incidence of grade 3/4 toxicities during preoperative chemotherapy were available from six studies (<a href="./references#CD008107-fig-0035" title="">Analysis 5.1</a>). The incidence ranged between zero (<a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>) and 1.96 (<a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>) events per patient. </p> <p>A formal sensitivity analysis according to risk of bias was not possible. One trial with a high risk of bias (<a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>) reported that no toxicity occurred during the preoperative chemotherapy, whereas all trials with moderate or low risk of bias from which data were available reported some degree of toxicity. The two trials with low risk of bias (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>) reported an incidence of 0.42 and 1.52 events per patient, respectively. </p> </section> <section id="CD008107-sec-0091"> <h5 class="title">Non‐administration of postoperative therapy</h5> <p>Five trials (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>; <a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>) stipulated postoperative continuation of chemotherapy in their intervention arm. For only three of those trials (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>), sufficient information was available regarding frequency of non‐administration of planned postoperative therapy. In the <a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a> trial, 25/113 patients (22.1%) received all four postoperative chemotherapy cycles as planned. In the <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a> trial, 104/250 (41.6%) patients received all three postoperative chemotherapy cycles as planned. In the <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a> trial, 28/115 (24.3%) patients received both postoperative chemotherapy cycles as planned. </p> </section> <section id="CD008107-sec-0092"> <h5 class="title">Fixed‐effect models</h5> <p>We repeated all analyses using fixed‐effect models. The only appreciable differences noted were that the 95% CI for disease‐free survival narrowed to 0.72 to 0.97 and reached statistical significance at P = 0.02, that the OR for tumor‐free margin changed to 1.29 (95% CI 1.04 to 1.60), and that the OR for postoperative N0 versus N1/2/3 stage changed to 2.00 (95% CI 1.58 to 2.55). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008107-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008107-sec-0093"></div> <p>The present meta‐analysis uses IPD to assess potential therapeutic benefits of perioperative chemotherapy for gastroesophageal adenocarcinoma. Unlike previous meta‐analyses (<a href="./references#CD008107-bbs2-0064" title="SjoquistKM , BurmeisterBH , SmithersBM , ZalcbergJR , SimesRJ , BarbourA , et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta‐analysis. Lancet Oncology2011;7:681‐92. ">Sjoquist 2011</a>; <a href="./references#CD008107-bbs2-0069" title="ThirionPG , MichielsS , LeMaîtreA , TierneyJ , on behalf of the MetaAnalysis of Chemotherapy in Esophagus Cancer Collaborative Group. Individual patient data‐based meta‐analysis assessing pre‐operative chemotherapy in resectable oesophageal carcinoma. Journal of Clinical Oncology2007;25(18S):4512. ">Thirion 2007</a>; <a href="./references#CD008107-bbs2-0076" title="WuAW , XuGW , WangHY , JiJF , TangJL . WITHDRAWN: Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005047.pub3] ">Wu 2007</a>), it includes all tumor locations, i.e. esophagus, gastroesophageal (GE) junction, and stomach. Due to the availability of individual patient data (IPD) from several trials in esophageal cancer, it was possible to include patients with adenocarcinoma from trials with mixed histology, while excluding patients with squamous cell carcinoma, which is thought to have a different biological behavior (<a href="./references#CD008107-bbs2-0031" title="ChauI , NormanAR , CunninghamD , OatesJ , HawkinsR , IvesonT , et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago‐gastric junction and gastric adenocarcinoma‐‐individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology2009;20(5):885‐91. ">Chau 2009</a>). </p> <p>The principal and clinically most important finding of our meta‐analysis is that perioperative chemotherapy, with or without radiotherapy, for gastroesophageal adenocarcinoma was associated with prolonged overall survival. The cumulative survival curve, based on IPD from more than 1000 patients, showed a sustained benefit for patients who received perioperative chemotherapy, starting at about 18 months after surgery and lasting as long as 10 years. The magnitude of this benefit was roughly 9%. For example, five‐year survival was 23% in the surgery alone group and 32% in the perioperative chemotherapy group. Given the very poor overall long‐term prognosis of the disease, this difference must be considered as clinically highly relevant. A very similar association was found for disease‐free survival, which strengthens the validity of our results. Therefore, perioperative chemotherapy should be offered to all patients with locoregionally advanced gastroesophageal adenocarcinoma unless medical contraindications are present. </p> <p>Several potential mechanisms of how perioperative chemo(radio)therapy could lead to prolonged survival in this tumor entity have been discussed (<a href="./references#CD008107-bbs2-0037" title="EguchiT , KoderaY , NakanishiH , YokoyamaH , OhashiN , ItoY , et al. The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo2008;22(6):707‐12. [PUBMED: 19180995] ">Eguchi 2008</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>). Some of these hypotheses are supported by our results. The odds of complete resection in patients treated with perioperative chemotherapy were about 1.4 times higher than in untreated patients, with borderline statistical significance in the meta‐analysis. A pooled analysis of patients from both treatment arms of trials for which respective data were available showed that complete resection is in fact a very strong predictor of survival. Regarding down‐staging of T and N stages and histopathologic response, there were insufficient direct data available from the single trials. We were however able to compare T and N stages upon resection between treatment arms and found a considerably higher incidence of more advanced stages in patients who were not pretreated with perioperative chemotherapy. As there is no reason to assume relevant baseline differences in T and N stage in the included randomized controlled trials (RCTs), this finding is an indirect proof of down‐staging. No data were available to us on the effect of perioperative chemotherapy on cancer symptoms, and on potential improvement of patients' performance status and quality of life, which in itself seems to be positively associated with survival and better surgical outcome (<a href="./references#CD008107-bbs2-0030" title="ChauI , NormanAR , CunninghamD , WatersJS , OatesJ , RossPJ . Multivariate prognostic factor analysis in locally advanced and metastatic esophago‐gastric cancer‐‐pooled analysis from three multicenter, randomized, controlled trials using individual patient data. Journal of Clinical Oncology2004;22(12):2395‐403. [PUBMED: 15197201] ">Chau 2004</a>; <a href="./references#CD008107-bbs2-0034" title="DjarvT , MetcalfeC , AveryKN , LagergrenP , BlazebyJM . Prognostic value of changes in health‐related quality of life scores during curative treatment for esophagogastric cancer. Journal of Clinical Oncology2010;28(10):1666‐70. [PUBMED: 20194863] ">Djarv 2010</a>; <a href="./references#CD008107-bbs2-0048" title="McCullochP , WardJ , TekkisPP . Mortality and morbidity in gastro‐oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ (Clinical research ed.)2003;327(7425):1192‐7. [PUBMED: 14630753] ">McCulloch 2003</a>), during preoperative treatment. </p> <p>There were no tangible differences in perioperative morbidity and mortality between treated and untreated patients, which largely excludes relevant detrimental effects of the treatment on the incidence of perioperative complications. Thus, fears that pretreating patients with chemotherapy before resection of gastroesophageal malignancies jeopardizes their perioperative safety do not seem to be justified. Specifically, we could not find any evidence for excessive postoperative mortality after preoperative chemoradiotherapy from the three trials for which such data were available. Specific regimens or schemes might be more favorable with regard to perioperative outcomes than others, an assumption which could not be further assessed in our data due to the heterogeneity of applied treatment protocols in the single trials. Information on how well perioperative chemotherapy itself was tolerated was available only from few trials and showed relevant heterogeneity with reported incidences of grade 3/4 toxicities ranging from as low as one in 10 patients to as high as two per patient. </p> <p>A strength of our IPD‐based analytical approach is that we were able to assess survival effects of perioperative chemotherapy in various clinically relevant prespecified subgroups both according to patient and treatment characteristics. As a note of caution, it must be kept in mind that these subgroup analyses were not planned for in most individual trials. Due to small numbers of patients in the single subgroups, some of the analyses lack the statistical power to detect associations of small magnitude. Likewise, direct comparisons of treatment effects between single subgroups need to be prudently appreciated, as there might be substantial confounding. Probably the most important finding was that the beneficial effect of perioperative chemotherapy on overall survival was largely consistent across most subgroups, which supports the broad application of this modality in patients with gastroesophageal adenocarcinoma. Of note, however, age showed an interaction with the effect of perioperative chemotherapy in the multivariable analysis, with the effect on overall survival being much more pronounced in patients of younger age and with no apparent effect in older patients. Although it cannot be shown with our data, toxicity might play an important role in this interaction. The finding supports the common clinical practice of critically evaluating the decision for perioperative chemotherapy above a certain age. Obviously, chronological age is a mere proxy for biological age and a person's overall health status and there should not be any strict age limits regarding eligibility for perioperative chemotherapy. </p> <p>With respect to tumor site, the treatment effect seems to be largest for GE junction tumors, followed by esophageal and gastric tumors. Other than expecting potential bias inherent to the analytical approach and explained above, these results need to be interpreted with additional caution because distinction of the precise tumor site between distal esophagus, GE junction, and proximal stomach, usually done according to the Siewert classification (<a href="./references#CD008107-bbs2-0062" title="SiewertJR , HolscherAH , BeckerK , GossnerW . Cardia cancer: attempt at a therapeutically relevant classification [Kardiacarcinom: Versuch einer therapeutisch relevanten Klassifikation]. Chirurg1987;58(1):25‐32. ">Siewert 1987</a>), is sometimes difficult in the pre‐therapeutic setting especially when endoscopic conditions are sub‐optimal. In the different trials included in our meta‐analysis, inclusion criteria and exact classification of tumor site varied and were not always specified in detail in the respective publications, which might introduce additional heterogeneity </p> <p>Regarding which specific perioperative chemotherapy regimen is most effective, our meta‐analysis can only provide limited information. The vast majority of included RCTs (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>; <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>; <a href="./references#CD008107-bbs2-0014" title="ZhaoWH , WangSF , DingW , ShengJM , MaZM , TengLS , et al. Apoptosis induced by preoperative oral 5'‐DFUR administration in gastric adenocarcinoma and its mechanism of action. World Journal of Gastroenterology2006;12(9):1356‐61. ">Zhao 2006</a>) used platinum‐based non‐anthracycline regimens, usually a combination of 5‐FU and cisplatin in varying intensity. Their results were very homogeneous. With the exception of one trial (<a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>), all of these RCTs yielded a hazard ratio (HR) smaller than one, which speaks in favor of the efficacy of this combination. One large trial (<a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>) added epirubicin to the 5‐FU/cisplatin doublet, which yielded a slightly lower HR. However, such an indirect comparison is insufficient to state that this triplet regimen is indeed more effective. The two studies preoperatively using only a fluorouracil‐derivate (<a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0013" title="WangXL , WuGX , ZhangMD , GuoM , ZhangH , SunXF . A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports2000;7(2):241‐4. ">Wang 2000</a>) showed mixed results but were also small. The only trial which used an anthracycline‐based non‐platinum regimen, i.e. FAMTX, showed a trend towards poorer survival in the intervention arm and was thus stopped early (<a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>). On these grounds, the regimen has been discarded for further use in gastroesophageal adenocarcinoma. Recently, taxane‐based schemes have gained popularity also in gastroesophageal adenocarcinoma. One of the included RCTs (<a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>) used a combination of docetaxel, cisplatin, and 5‐FU and yielded a HR of 0.79. However, its statistical power was too small to reach statistical significance. An ongoing phase three trial (NCT01216644) compares the ECF scheme that was used in the MAGIC trial to the docetaxel‐based FLOT scheme with pathologic complete response as primary endpoint. To what extent the addition of postoperative chemotherapy to preoperative treatment is beneficial must remain open. Five of the 14 included trials (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0005" title="FengL‐M , LiG , SunX‐C , ZhuS‐G . Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment2008;15(13):1022‐4. ">Feng 2008</a>; <a href="./references#CD008107-bbs2-0006" title="KobayashiT . Long‐term outcome of preoperative chemotherapy with 5'‐deoxy‐5‐fluorouridine (5'‐DFUR) for gastric cancer. Gan to Kagaku Ryoho2000;27(10):1521‐6. ">Kobayashi 2000</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>) foresaw postoperative chemotherapy. The subgroup comparison with trials in which patients were treated only preoperatively showed no relevant differences. It must be noted that only a minority of patients in fact received the planned postoperative treatment to its full extent. Therefore, its role remains debatable. However, since two large positive trials (<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>) had used a treatment scheme including postoperative chemotherapy, it remains common clinical practice to offer postoperative continuation of chemotherapy to eligible patients. </p> <p>In the subgroup analysis of perioperative schemes with or without inclusion of radiotherapy, the treatment effect seems to be larger for combined chemoradiotherapy. However, all included trials using chemoradiotherapy comprised exclusively patients with esophageal or GE junction tumors, which inevitably leads to substantial confounding. In our multivariable model, chemoradiotherapy is not associated with improved overall survival compared to surgery alone. This result is however based on a single negative trial (<a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>) and disregards three positive trials, from which the variables required for the model were unavailable (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>; <a href="./references#CD008107-bbs2-0012" title="WalshTN , GrennellM , MansoorS , KellyA . Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus2002;15(2):121‐4. ">Walsh 2002</a>), which makes its interpretation difficult. After closure of our database, two other RCTs comparing preoperative chemoradiotherapy followed by surgery with surgery alone were published. The CROSS trial showed a significant survival advantage in the chemoradiotherapy arm, with a HR of 0.73 for the subgroup of patients with adenocarcinoma, which made up for 75% of patients in the trial (<a href="./references#CD008107-bbs2-0021" title="vanHagenP , HulshofMCCM , vanLanschotJJB , SteyerbergEW , HenegouwenMI , WijnhovenBPL , et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine2012;366(22):2074‐84. ">van Hagen 2012</a>). The FFCD 9901 trial, which has so far only been published in abstract form (<a href="./references#CD008107-bbs2-0019" title="MarietteC , SeitzJF , MaillardE , MornexF , ThomasPA , RaoulJ , et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. ASCO Meeting Abstracts2010;28(15 Suppl):4005. ">Mariette 2010</a>), found no survival advantage for patients in the chemoradiotherapy arm. However, it did not include GE junction tumors, 75% of patients had squamous cell carcinoma, and two‐thirds of patients had a node‐negative tumor stage. Therefore, the interpretation of its results with regard to the setting of our meta‐analysis, locoregionally advanced gastroesophageal adenocarcinoma, is difficult. </p> <p>To demonstrate superiority of either perioperative chemoradiotherapy or chemotherapy was not within the scope of this meta‐analysis. To date, there are only two randomized trials directly comparing the two modalities (<a href="./references#CD008107-bbs2-0029" title="BurmeisterBH , ThomasJM , BurmeisterEA , WalpoleET , HarveyJA , ThomsonDB , et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European Journal of Cancer2011;47(3):354‐60. ">Burmeister 2011</a>; <a href="./references#CD008107-bbs2-0067" title="StahlM , WalzMK , StuschkeM , LehmannN , MeyerHJ , Riera‐KnorrenschildJ , et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Journal of Clinical Oncology2009;27(6):851‐6. ">Stahl 2009</a>). Both trials stipulated cisplatin‐based chemotherapy schemes, included esophageal and GE junction tumors, and closed early due to slow recruitment. In a German phase three trial (<a href="./references#CD008107-bbs2-0067" title="StahlM , WalzMK , StuschkeM , LehmannN , MeyerHJ , Riera‐KnorrenschildJ , et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Journal of Clinical Oncology2009;27(6):851‐6. ">Stahl 2009</a>) the targeted statistical power for analysis of the primary outcome overall survival was not achieved. Nonetheless, patients in the chemoradiotherapy arm of the trial had a survival advantage of 20% at three years with borderline statistical significance (P = 0.07). The Australian trial (<a href="./references#CD008107-bbs2-0029" title="BurmeisterBH , ThomasJM , BurmeisterEA , WalpoleET , HarveyJA , ThomsonDB , et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European Journal of Cancer2011;47(3):354‐60. ">Burmeister 2011</a>) was a randomized phase two trial which primarily assessed response and tolerability. No significant survival differences were found. Of note, both trials showed a markedly higher likelihood of pathological response in the chemoradiotherapy groups. A recent meta‐analysis included both trials and used specific techniques for an indirect comparison between perioperative chemotherapy and chemoradiotherapy for esophageal carcinoma of both histologic subtypes (<a href="./references#CD008107-bbs2-0064" title="SjoquistKM , BurmeisterBH , SmithersBM , ZalcbergJR , SimesRJ , BarbourA , et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta‐analysis. Lancet Oncology2011;7:681‐92. ">Sjoquist 2011</a>). It showed a combined HR of 0.88 which was borderline significant (P = 0.07). In summary, the available evidence suggests a benefit from adding radiotherapy to perioperative chemotherapy for adenocarcinoma of the esophagus and GE junction. However, due to limitations in the evidence level, no clear conclusion can be made and further RCTs directly comparing the two modalities are strongly required. To what extent perioperative chemoradiotherapy might be an appropriate treatment alternative for gastric adenocarcinoma remains an open question, as there is no higher‐level evidence. A number of phase two trials showed promising pathologic response rates and adequate tolerability (<a href="./references#CD008107-bbs2-0024" title="AjaniJA , MansfieldPF , JanjanN , MorrisJ , PistersPW , LynchPM , et al. Multi‐institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. Journal of Clinical Oncology2004;22(14):2774‐80. ">Ajani 2004</a>; <a href="./references#CD008107-bbs2-0025" title="AjaniJA , MansfieldPF , CraneCH , WuTT , LunagomezS , LynchPM , et al. Paclitaxel‐based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. Journal of Clinical Oncology2005;23(6):1237‐44. ">Ajani 2005</a>; <a href="./references#CD008107-bbs2-0026" title="AjaniJA , WinterK , OkawaraGS , DonohueJH , PistersPW , CraneCH , et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. Journal of Clinical Oncology2006;24(24):3953‐8. ">Ajani 2006</a>), but as of today the concept has not been investigated in phase three trials. </p> <p>In a multivariable analysis, we aimed to assess the independent influence of perioperative chemotherapy and other covariates on overall survival. Interestingly, in the final model, the effect of perioperative chemotherapy is slightly diminished in its magnitude and loses statistical significance. Other factors, specifically tumor site, age, and performance status, retain a significant effect on overall survival. From a clinical viewpoint, this is very plausible and intuitive. It should however not deter from recommending perioperative chemotherapy to eligible patients, as the achievable survival benefit is of a highly relevant magnitude in a disease with a still unacceptably poor oncological outcome. </p> <p>A pooled analysis including all patients for whom respective information was available showed that patients with R1 and R2 resection have a substantially shorter survival than those with complete resection. This emphasizes that microscopically complete resection should always be the goal when planning surgery in a patient with gastroesophageal adenocarcinoma. For patients in whom complete resection seems doubtful based on preoperative staging, the indication for resection must be critically evaluated. Given the non‐negligible postoperative morbidity and the common early postoperative decrease in quality of life (<a href="./references#CD008107-bbs2-0035" title="DjarvT , LagergrenP . Quality of life after esophagectomy for cancer. Expert Review of Gastroenterology and Hepatology2012;6(1):115‐22. [PUBMED: 22149587] ">Djarv 2012</a>; <a href="./references#CD008107-bbs2-0049" title="MuneneG , FrancisW , GarlandSN , PelletierG , MackLA , BatheOF . The quality of life trajectory of resected gastric cancer. Journal of Surgical Oncology2012;105(4):337‐41. [PUBMED: 22095440] ">Munene 2012</a>), palliative resection should be reserved for patients with substantial tumor symptoms which can be expected to improve after surgery. </p> <p>Perioperative chemotherapy competes with exclusively adjuvant, i.e. postoperative, treatment modalities for gastroesophageal adenocarcinoma. Both adjuvant chemotherapy and chemoradiotherapy have been evaluated in randomized trials. Based on positive results from a large phase three trial (<a href="./references#CD008107-bbs2-0045" title="MacdonaldJS , SmalleySR , BenedettiJ , HundahlSA , EstesNC , StemmermannGN , et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine2001;345(10):725‐30. ">Macdonald 2001</a>), adjuvant chemoradiotherapy for adenocarcinoma of the stomach and GE junction has gained wide popularity in the United States. In Europe, the modality has not been widely adopted, as the trial included a large proportion of patients who had received only D1 lymphadenectomy, which is deemed insufficient according to European standards. The ongoing Dutch‐Swedish multicenter CRITICS trial evaluates if the addition of postoperative chemoradiotherapy to perioperative chemotherapy confers a survival benefit in a setting where a high rate of D2 lymphadenectomies is expected (<a href="./references#CD008107-bbs2-0033" title="DikkenJL , vanSandickJW , Maurits SwellengrebelHA , LindPA , PutterH , JansenEP , et al. Neo‐adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer2011;11:329. [PUBMED: 21810227] ">Dikken 2011</a>). Adjuvant chemotherapy is the standard of care for advanced gastric adenocarcinoma in Asia, where preoperative treatment is uncommon. A recent IPD meta‐analysis including 17 RCTs comparing postoperative chemotherapy with surgery alone for gastric adenocarcinoma showed a 7.4% benefit in 10‐year overall survival for patients receiving postoperative chemotherapy (<a href="./references#CD008107-bbs2-0051" title="PaolettiX , ObaK , BurzykowskiT , MichielsS , OhashiY , PignonJP , et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta‐analysis. JAMA2010;303(17):1729‐37. ">Paoletti 2010</a>). A sufficiently powered randomized direct comparison between preoperative and postoperative chemotherapy has not been conducted, and thus superiority of one or the other modality cannot be deducted. One factor often hampering postoperative modalities in clinical practice is that only a small percentage of eligible patients receive the planned therapy, mostly because of poor performance status or low compliance in the postoperative period during which adjuvant treatment should commence. In a prematurely halted RCT comparing preoperative with postoperative taxane‐based chemotherapy for gastric adenocarcinoma, 97 per cent of patients randomized for preoperative treatment received chemotherapy, whereas this was the case only for 66 per cent of patients randomized for postoperative treatment (<a href="./references#CD008107-bbs2-0028" title="BiffiR , FazioN , LucaF , ChiappaA , AndreoniB , ZampinoMG , et al. Surgical outcome after docetaxel‐based neoadjuvant chemotherapy in locally‐advanced gastric cancer. World Journal of Gastroenterology2010;16(7):868‐74. [PUBMED: 20143466] ">Biffi 2010</a>). The extent of this problem is emphasized by our findings, which show that in the three trials stipulating postoperative chemotherapy in their protocol, only 22 to 42 per cent of patients actually received all planned cycles. Conversely, one argument often raised against preoperative treatment, namely the fear of elevated postoperative morbidity, is not supported by our results, which do not show a higher risk of complications in pretreated patients. </p> <p>The strength of our meta‐analysis is its rigorous methodology. By adhering to Cochrane standards, we are confident that all available studies meeting our inclusion criteria have been identified and included in the analyses. We included only RCTs in our meta‐analysis, which results in the highest possible evidence level. IPD meta‐analysis is considered to have numerous advantages over meta‐analysis of aggregate data (<a href="./references#CD008107-bbs2-0058" title="RileyRD , LambertPC , Abo‐ZaidG . Meta‐analysis of individual participant data: rationale, conduct, and reporting. BMJ2010;340:c221. ">Riley 2010</a>). It allows for uniform inclusion criteria across trials, to verify data consistency, and to use updated follow‐up data from the single trials. Most importantly, in our specific case the availability of IPD enabled us to include patients with adenocarcinoma from trials with carcinomas of mixed histology in our meta‐analysis of the primary and secondary outcomes as well as in the subgroup analyses (<a href="./references#CD008107-bbs2-0002" title="TepperJ , KrasnaMJ , NiedzwieckiD , HollisD , ReedCE , GoldbergR , et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology2008;26(7):1086‐92. ">CALGB 9781 2008</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0011" title="UrbaSG , OrringerMB , TurrisiA , IannettoniM , ForastiereA , StrawdermanM . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology2001;19(2):305‐13. ">Urba 2001</a>). We solicited IPD from all trialists, and repeatedly followed up our requests in case of no or evasive reply. By doing so, we were able to receive IPD from about 60 per cent of trials. Unfortunately, we were unable to obtain IPD from the two largest trials (<a href="./references#CD008107-bbs2-0007" title="CunninghamD , AllumWH , StenningSP , ThompsonJN , Van deVeldeCJ , NicolsonM , et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine2006;355(1):11‐20. ">MAGIC 2006</a>; <a href="./references#CD008107-bbs2-0008" title="AllumWH , StenningSP , BancewiczJ , ClarkPI , LangleyRE . Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology2009;27(30):5062‐7. ">OE02 2009</a>), and thus IPD were available for only about 45 per cent of patients. This rather low yield seems at first disappointing, but is a problem not unfamiliar to IPD meta‐analysts. Instead of limiting our analyses to trials which had provided IPD, we chose to combine IPD and aggregate data with the so‐called two‐stage method (<a href="./references#CD008107-bbs2-0057" title="RileyRD , SimmondsMC , LookMP . Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. Journal of Clinical Epidemiology2007;60:431‐9. ">Riley 2007</a>). We believe that this approach draws the most comprehensive picture by incorporating all available evidence and lending sufficient statistical power to the analyses. A sensitivity analysis showed that there were no tangible differences when analyzing IPD and aggregate data separately, which supports the use of the two‐stage method in this case. </p> <p>Including trials on patients with adenocarcinoma of three anatomically different locations, esophagus, GE junction, and stomach, into one joint meta‐analysis bears a risk of heterogeneity. This risk is augmented by the fact that surgical approaches are different between stomach, GE junction, and esophageal tumors, and that particularly for GE junction and esophageal tumors, surgical techniques differed vastly between trials and even between participating centers or single patients within specific trials. Similarly, the definitions used for stratifying tumors into different locations (esophagus, GE junction, stomach) differed between trials. Therefore, although statistical heterogeneity was rather low for most outcomes and subgroup analyses, there might be relevant clinical heterogeneity. In fact, our results suggest treatment effects differ between the three tumor locations. Nevertheless, given that gastroesophageal adenocarcinoma is frequently treated according to the same chemotherapeutical protocol irrespective of the exact tumor location, we deem it a valid approach to include all tumor locations into one joint meta‐analysis. This approach is supported by the finding that tumor site does not predict survival outcome for patients with gastroesophageal adenocarcinoma treated with chemotherapy in the palliative setting (<a href="./references#CD008107-bbs2-0031" title="ChauI , NormanAR , CunninghamD , OatesJ , HawkinsR , IvesonT , et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago‐gastric junction and gastric adenocarcinoma‐‐individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology2009;20(5):885‐91. ">Chau 2009</a>). The subgroup analysis we conducted helps in identifying patient populations in which treatment effects are particularly pronounced or diminished. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD008107-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008107-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgments about each risk of bias item for each included study." data-id="CD008107-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD008107-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Overall survival, outcome: 1.1 Hazard ratio plot for overall survival." data-id="CD008107-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Overall survival, outcome: 1.1 Hazard ratio plot for overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Simple (non‐stratified) overall survival curves of perioperative chemotherapy plus surgery versus surgery alone (perioperative chemo: 372 events, 525 total; surgery alone: 405 events, 524 total; hazard ratio 0.80, 95% CI 0.69 to 0.93)." data-id="CD008107-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Simple (non‐stratified) overall survival curves of perioperative chemotherapy plus surgery versus surgery alone (perioperative chemo: 372 events, 525 total; surgery alone: 405 events, 524 total; hazard ratio 0.80, 95% CI 0.69 to 0.93). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Overall survival curves by type of resection: 719 patients with R0, R1 or R2, 99 patients not resected or missing (R0: 390 events, 611 total; R1: 43 events, 46 total; R2: 60 events, 62 total)." data-id="CD008107-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Overall survival curves by type of resection: 719 patients with R0, R1 or R2, 99 patients not resected or missing (R0: 390 events, 611 total; R1: 43 events, 46 total; R2: 60 events, 62 total). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Hazard ratio with 95% confidence interval for perioperative chemo(radio)therapy versus surgery alone for age in 5‐year increments." data-id="CD008107-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Hazard ratio with 95% confidence interval for perioperative chemo(radio)therapy versus surgery alone for age in 5‐year increments. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Disease‐free survival (landmark time 6 months), outcome: 2.1 Hazard ratio plot for disease‐free survival (landmark time 6 months)." data-id="CD008107-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Disease‐free survival (landmark time 6 months), outcome: 2.1 Hazard ratio plot for disease‐free survival (landmark time 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Presence of tumor‐free resection margin, outcome: 3.1 Odds ratio plot for tumor‐free resection margin." data-id="CD008107-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Presence of tumor‐free resection margin, outcome: 3.1 Odds ratio plot for tumor‐free resection margin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 4 Tumor stage at resection, outcome: 4.1 Odds ratio plot for tumor stage T0/T1/T2." data-id="CD008107-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Funnel plot of comparison: 4 Tumor stage at resection, outcome: 4.1 Odds ratio plot for tumor stage T0/T1/T2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 4 Tumor stage at resection, outcome: 4.2 Odds ratio plot for nodal status N0." data-id="CD008107-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Funnel plot of comparison: 4 Tumor stage at resection, outcome: 4.2 Odds ratio plot for nodal status N0. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Postoperative morbidity, outcome: 6.1 Risk difference plot for postoperative morbidity." data-id="CD008107-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Postoperative morbidity, outcome: 6.1 Risk difference plot for postoperative morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 7 Postoperative mortality, outcome: 7.1 Risk difference plot for postoperative mortality." data-id="CD008107-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Funnel plot of comparison: 7 Postoperative mortality, outcome: 7.1 Risk difference plot for postoperative mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 1 Hazard ratio plot for overall survival." data-id="CD008107-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 1 Hazard ratio plot for overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 2 Hazard ratio plot for overall survival by type of data." data-id="CD008107-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 2 Hazard ratio plot for overall survival by type of data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 3 Hazard ratio plot for overall survival by tumor site." data-id="CD008107-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 3 Hazard ratio plot for overall survival by tumor site. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 4 Interaction treatment‐tumor site (only IPD)." data-id="CD008107-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 4 Interaction treatment‐tumor site (only IPD).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 5 Hazard ratio plot for overall survival by chemo‐/radiotherapy." data-id="CD008107-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 5 Hazard ratio plot for overall survival by chemo‐/radiotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 6 Hazard ratio plot for overall survival by timing of regimen." data-id="CD008107-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 6 Hazard ratio plot for overall survival by timing of regimen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 7 Hazard ratio plot for overall survival by chemotherapeutic agents." data-id="CD008107-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 7 Hazard ratio plot for overall survival by chemotherapeutic agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 8 Hazard ratio plot for overall survival by performance status (only IPD)." data-id="CD008107-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 8 Hazard ratio plot for overall survival by performance status (only IPD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 9 Interaction treatment‐performance status (only IPD)." data-id="CD008107-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 9 Interaction treatment‐performance status (only IPD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 10 Hazard ratio plot for overall survival by age (only IPD)." data-id="CD008107-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 10 Hazard ratio plot for overall survival by age (only IPD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 11 Interaction treatment‐age (only IPD)." data-id="CD008107-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 11 Interaction treatment‐age (only IPD).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 12 Hazard ratio plot for overall survival by sex (only IPD)." data-id="CD008107-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 12 Hazard ratio plot for overall survival by sex (only IPD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 13 Interaction treatment‐sex (only IPD)." data-id="CD008107-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 13 Interaction treatment‐sex (only IPD).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 14 Hazard ratio plot for overall survival by pretreatment T class (only IPD)." data-id="CD008107-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 14 Hazard ratio plot for overall survival by pretreatment T class (only IPD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 15 Interaction treatment‐T class (only IPD)." data-id="CD008107-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 15 Interaction treatment‐T class (only IPD).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 16 Hazard ratio plot for overall survival by pretreatment N class (only IPD)." data-id="CD008107-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 16 Hazard ratio plot for overall survival by pretreatment N class (only IPD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 17 Interaction treatment‐N class (only IPD)." data-id="CD008107-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 17 Interaction treatment‐N class (only IPD).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disease‐free survival (landmark time 6 months), Outcome 1 Hazard ratio plot for disease‐free survival (landmark time 6 months)." data-id="CD008107-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Disease‐free survival (landmark time 6 months), Outcome 1 Hazard ratio plot for disease‐free survival (landmark time 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Presence of tumor‐free resection margin, Outcome 1 Odds ratio plot for tumor‐free resection margin." data-id="CD008107-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Presence of tumor‐free resection margin, Outcome 1 Odds ratio plot for tumor‐free resection margin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-004-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Tumor stage at resection, Outcome 1 Odds ratio plot for tumor stage T0/T1/T2." data-id="CD008107-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Tumor stage at resection, Outcome 1 Odds ratio plot for tumor stage T0/T1/T2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-004-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Tumor stage at resection, Outcome 2 Odds ratio plot for nodal status N0." data-id="CD008107-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Tumor stage at resection, Outcome 2 Odds ratio plot for nodal status N0. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0035"> <p> <div class="table" id="CD008107-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACCORD 07 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62/109 ˜ 0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CALGB 9781 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In publication: population with mixed histology, no stratified data available; in IPD: no data on toxicity available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC 40954 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FAMTX 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41/27 ˜ 1.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feng 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data on grade of toxicity available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kobayashi 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No complications were noted in the operative period related to preoperative dosage of 5'DFUR" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAGIC 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>330/237 who started treatment ˜1.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OE02 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTOG 8911 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>225/115 ˜ 1.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TROG‐AGITG 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In publication: population with mixed histology, no stratified data available; in IPD: no data on toxicity available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urba 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In publication: population with mixed histology, no stratified data available; in IPD: no data on toxicity available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walsh 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/58 ˜ 0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhao 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Safety of perioperative chemotherapy regimen, Outcome 1 Number of grade 3/4 toxicities per patient. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0035">Navigate to figure in review</a></div> </div> <div class="figure" id="CD008107-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-006-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Postoperative morbidity, Outcome 1 Risk difference plot for postoperative morbidity." data-id="CD008107-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Postoperative morbidity, Outcome 1 Risk difference plot for postoperative morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008107-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/urn:x-wiley:14651858:media:CD008107:CD008107-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_t/tCD008107-CMP-007-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Postoperative mortality, Outcome 1 Risk difference plot for postoperative mortality." data-id="CD008107-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Postoperative mortality, Outcome 1 Risk difference plot for postoperative mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/media/CDSR/CD008107/image_n/nCD008107-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008107-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus <br/> <b>Settings:</b> <br/> <b>Intervention:</b> perioperative chemotherapy <br/> <b>Comparison:</b> primary surgery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Primary surgery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Perioperative chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival among all patients</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.81</b> <br/> (0.73 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2422 <br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disease‐free survival (landmark time 6 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.84</b> <br/> (0.69 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>931 <br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by type of data ‐ Individual patient data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.80</b> <br/> (0.66 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1049 <br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by type of data ‐ Aggregated data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.81</b> <br/> (0.72 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1373 <br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by tumor site ‐ Esophagus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.87</b> <br/> (0.73 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>473 <br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by tumor site ‐ GE junction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.69</b> <br/> (0.54 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>470 <br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by tumor site ‐ Stomach</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.94</b> <br/> (0.82 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>828 <br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>GE:</b> gastroesophageal; <b>HR:</b> hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Four out of the six studies included in this analysis have a high overall risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008107-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus <br/> <b>Settings:</b> <br/> <b>Intervention:</b> perioperative chemotherapy <br/> <b>Comparison:</b> primary surgery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Primary surgery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Perioperative chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.83</b> <br/> (0.75 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2033 <br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.70</b> <br/> (0.50 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>389 <br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence of tumor‐free resection margin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 100</b> <br/> (67 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.42</b> <br/> (0.97 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1665 <br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tumor stage at resection (T0 to T2 vs T3 to T4)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b> <br/> (34 to 54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.53</b> <br/> (1.02 to 2.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1410 <br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tumor stage at resection (N0 vs N+)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 100</b> <br/> (25 to 47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.43</b> <br/> (1.48 to 3.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1507 <br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postoperative morbidity</b> <br/> RD </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 100</b> <br/> (28 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1397 <br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risks were calculated from pooled risk differences: RD 0.01 (‐0.03 to 0.05)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postoperative mortality</b> <br/> RD </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> <br/> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1606 <br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risks were calculated from pooled risk differences:RD 0.00 (‐0.01 to 0.02)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>HR:</b> hazard ratio; <b>RD:</b> risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Heterogeneous trial results. <br/> <sup>2</sup>Funnel plot suggests publication bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Perioperative chemotherapy compared to primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008107-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Median potential follow‐up time* in years for each trial with IPD</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median potential follow‐up time in years (95% confidence interval)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urba 2001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 (6.3 to 10.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Walsh 2002</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.6 (12.2 to 16.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAMTX 2004</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (8.3 to 10.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TROG‐AGITG 2005</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (4.4 to 6.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG 8911 2007</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 (8.1 to 9.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CALGB 9781 2008</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1 (5.5 to 6.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC 40954 2010</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4 (4.0 to 4.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACCORD 07 2011</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7 (5.1 to 6.6)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>*Follow‐up time calculated according to <a href="./references#CD008107-bbs2-0060" title="SchemperM , SmithTL . A note on quantifying follow‐up in studies of failure time. Controlled Clinical Trials1996;17:343‐6. ">Schemper 1996</a>. <br/> <br/> IPD: individual patient data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Median potential follow‐up time* in years for each trial with IPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008107-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adjusted hazard ratio (HR) for the treatment effect (death for perioperative chemotherapy versus surgery alone) in a Cox proportional hazards model</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjustment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI))</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For tumor site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>931 (326 esophagus, 352 GE junction, 253 stomach)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.70 to 0.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0117</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For cT stage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 (152 T0/1/2, 265 T3/4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.65 to 1.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1258</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For cN stage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453 (250 N0, 203 N1/2/3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.71 to 1.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3361</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For performance status</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>846 (595 PS 0, 251 PS 1/2/higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.73 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0651</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For age</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1049 (median 62, minimum 23, maximum 80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 (0.70 to 0.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0031</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For gender</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1049 (870 male, 179 female)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.69 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval; GE: gastroesophageal; PS: performance status</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adjusted hazard ratio (HR) for the treatment effect (death for perioperative chemotherapy versus surgery alone) in a Cox proportional hazards model</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008107-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Multivariable analysis: Cox proportional hazards model based on five trials* with 804 patients. Regression coefficients (β) with standard errors (SE) and hazard ratios (HR) for death with 95% confidence intervals (CI)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Univariable</b> </p> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multivariable</b> </p> <p><b>β (SE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multivariable</b> </p> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multivariable</b> </p> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment arm</p> <p>(chemotherapy only</p> <p>vs surgery alone)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>324 chemotherapy only,</p> <p>80 chemoradiotherapy,</p> <p>400 surgery alone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> <p>(0.70 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.16 (0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 <br/> (0.71 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0972</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment arm</p> <p>(chemoradiotherapy</p> <p>vs surgery alone)**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02</p> <p>(0.72 to 1.45)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (0.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99</p> <p>(0.69 to 1.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9351</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumor site</p> <p>(esophagus vs stomach)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>321 esophagus, <br/> 308 GE junction, <br/> 175 stomach </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.28</p> <p>(1.60 to 3.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.23 <br/> (1.55 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumor site</p> <p>(GE junction vs stomach)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> <p>(1.35 to 2.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56 (0.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.75</p> <p>(1.29 to 2.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0003</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance status</p> <p>(0 vs 1/2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>565 PS 0, <br/> 239 PS 1/2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> <p>(0.62 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.30 (0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> <p>(0.62 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0010</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age</p> <p>(continuous variable)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 61, <br/> Minimum 23, <br/> Maximum 81 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01</p> <p>(1.00 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (0.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (1.00 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0124</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gender</p> <p>(male vs female)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667 male, <br/> 137 female </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26</p> <p>(0.99 to 1.60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11 (0.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 (0.87 to 1.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3757</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>*<a href="./references#CD008107-bbs2-0001" title="YchouM , BoigeV , PignonJP , ConroyT , BoucheO , LebretonG , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology2011;29(13):1715‐21. ">ACCORD 07 2011</a>; <a href="./references#CD008107-bbs2-0003" title="SchuhmacherC , GretschelS , LordickF , ReichardtP , HohenbergerW , EisenbergerCF , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology2010;28(35):5210‐8. ">EORTC 40954 2010</a>; <a href="./references#CD008107-bbs2-0004" title="HartgrinkHH ,  van de VeldeCJ , PutterH , SongunI , TesselaarME , KranenbargEK , et al. Neo‐adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology2004;30(6):643‐9. ">FAMTX 2004</a>; <a href="./references#CD008107-bbs2-0009" title="KelsenDP , WinterKA , GundersonLL , MortimerJ , EstesNC , HallerDG , et al. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology2007;25(24):3719‐25. ">RTOG 8911 2007</a>; <a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a> </p> <p>**The group 'chemoradiotherapy' includes 80 patients from one single trial (<a href="./references#CD008107-bbs2-0010" title="BurmeisterBH , SmithersBM , GebskiV , FitzgeraldL , SimesRJ , DevittP , et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology2005;6(9):659‐68. ">TROG‐AGITG 2005</a>) </p> <p>GE: gastroesophageal; PS: performance status</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Multivariable analysis: Cox proportional hazards model based on five trials* with 804 patients. Regression coefficients (β) with standard errors (SE) and hazard ratios (HR) for death with 95% confidence intervals (CI)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/full#CD008107-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008107-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall survival</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hazard ratio plot for overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.73, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hazard ratio plot for overall survival by type of data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Individual patient data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.66, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Aggregated data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.72, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hazard ratio plot for overall survival by tumor site <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Esophagus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 GE junction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.54, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Stomach</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.82, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Interaction treatment‐tumor site (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Interaction coefficient (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.38, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hazard ratio plot for overall survival by chemo‐/radiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Chemotherapy only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.75, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Chemoradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.50, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hazard ratio plot for overall survival by timing of regimen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Preoperative regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.68, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Preoperative and postoperative combined regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.70, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hazard ratio plot for overall survival by chemotherapeutic agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Non‐platinum and non‐anthracycline regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Platinum‐based non‐anthracycline regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.72, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Anthracycline‐based non‐platinum regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.78, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Platinum‐ and anthracycline‐based regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hazard ratio plot for overall survival by performance status (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Performance status 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Performance status 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Interaction treatment‐performance status (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Interaction coefficient (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [‐0.03, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Hazard ratio plot for overall survival by age (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 65 to 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Interaction treatment‐age (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Interaction coefficient (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.40, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Hazard ratio plot for overall survival by sex (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Interaction treatment‐sex (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>849</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Interaction coefficient (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.59, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Hazard ratio plot for overall survival by pretreatment T class (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 T stage 0/1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 T stage 3/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Interaction treatment‐T class (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Interaction coefficient (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.57, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Hazard ratio plot for overall survival by pretreatment N class (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 N stage 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 N stage 1/2/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Interaction treatment‐N class (only IPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Interaction coefficient (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.63, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall survival</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008107-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Disease‐free survival (landmark time 6 months)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hazard ratio plot for disease‐free survival (landmark time 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.69, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Disease‐free survival (landmark time 6 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008107-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Presence of tumor‐free resection margin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Odds ratio plot for tumor‐free resection margin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.97, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Presence of tumor‐free resection margin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008107-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tumor stage at resection</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Odds ratio plot for tumor stage T0/T1/T2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.02, 2.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Odds ratio plot for nodal status N0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [1.48, 3.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tumor stage at resection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008107-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Safety of perioperative chemotherapy regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of grade 3/4 toxicities per patient <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Safety of perioperative chemotherapy regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008107-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Postoperative morbidity</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Risk difference plot for postoperative morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.03, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Postoperative morbidity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008107-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Postoperative mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Risk difference plot for postoperative mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Postoperative mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008107.pub2/references#CD008107-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008107.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008107-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008107-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008107-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008107-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008107\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008107\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008107\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008107\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008107\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=u3GUW7vS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008107.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008107.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008107.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008107.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008107.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716698319"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008107.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716698323"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008107.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da5d49dbd9368',t:'MTc0MDcxNjY5OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 